Louisiana Tech University

Louisiana Tech Digital Commons
Doctoral Dissertations

Graduate School

Spring 2009

Nano-formulation and controlled delivery of low
solubility anticancer drugs
Anshul Agarwal
Louisiana Tech University

Follow this and additional works at: https://digitalcommons.latech.edu/dissertations
Part of the Biomedical Engineering and Bioengineering Commons, and the Oncology Commons
Recommended Citation
Agarwal, Anshul, "" (2009). Dissertation. 484.
https://digitalcommons.latech.edu/dissertations/484

This Dissertation is brought to you for free and open access by the Graduate School at Louisiana Tech Digital Commons. It has been accepted for
inclusion in Doctoral Dissertations by an authorized administrator of Louisiana Tech Digital Commons. For more information, please contact
digitalcommons@latech.edu.

NANO-FORMULATION AND CONTROLLED
DELIVERY OF LOW SOLUBILITY
ANTICANCER DRUGS
By
Anshul Agarwal, M.D., M.S.

A Dissertation Presented in Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy

COLLEGE OF ENGINEERING AND SCIENCE
LOUISIANA TECH UNIVERSITY

May 2009

UMI Number: 3360806

INFORMATION TO USERS

The quality of this reproduction is dependent upon the quality of the copy
submitted. Broken or indistinct print, colored or poor quality illustrations and
photographs, print bleed-through, substandard margins, and improper
alignment can adversely affect reproduction.
In the unlikely event that the author did not send a complete manuscript
and there are missing pages, these will be noted. Also, if unauthorized
copyright material had to be removed, a note will indicate the deletion.

®

UMI

UMI Microform 3360806
Copyright2009by ProQuest LLC
All rights reserved. This microform edition is protected against
unauthorized copying under Title 17, United States Code.

ProQuest LLC
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor, Ml 48106-1346

LOUISIANA TECH UNIVERSITY
THE GRADUATE SCHOOL

March 31 st 2009
Date

We

hereby

recommend

that

the

dissertation

prepared

under

our

supervision

Anshul A g a r w a l

by_
entitled

"NANO - FORMULATION AND CONTROLLED DELIVERY OF LOW SOLUBILITY
ANTICANCER DRUGS"

be

accepted

in

partial

fulfillment

of

the

requirements

for

the

Degree

of

Doctor of Philosophy in Biomedical Engineering

Head of Department
Biomedical Engineering
Department
Recommendationconcurred in

Advisory Committee

Approved:

.^Director of Graduate Studies

Approved:

raduate\3chool
Dean of the Graduate

»

^ y ^

Dean of the College ^
GSForm 13a
(6/07)

ABSTRACT
Optimal drug delivery and reduction of systemic adverse effects have been age old
problems in chemotherapeutics in all types of human cancer. During chemotherapy, using
water insoluble drugs like paclitaxel and tamoxifen, it has been realized that better
formulations are needed for more specific and controlled drug delivery of these agents. In
a novel approach to form high content stable nanocolloids of these drugs with
controllable release rate, a sonicated layer-by-layer (LbL) polyelectrolyte coating
technology is suggested. The desired features of pharmaceutical carriers for intravenous
administration include their small size and biodegradability, good loading capacity for a
given drug, high content of a drug in a final preparation, prolonged circulation in the
blood, and ability to gradually concentrate in required areas (targeting) via passive
accumulation. While these requirements are reasonably well met by a variety of drug
carriers (liposomes, microcapsules, nanoparticles) developed for water-soluble drugs, the
development of nanoparticulate drug carriers displaying all of these properties for the
delivery of poorly soluble pharmaceuticals still represents a challenge.
Intravenous administration of these intrinsically hydrophobic agents is frequently
associated with serious problems. One of these problems is that the diameter of blood
capillaries is only a few micrometers or less, and intravenous administration of
aggregates of undissolved material that form in an aqueous media would cause
embolization

before

reaching

and

penetrating

iii

a

target,

such

as

tumor.

iv
Additionally, the low solubility of hydrophobic drugs in combination with excretion and
metabolic degradation often does not allow for achieving therapeutically significant
systemic concentrations. As a result, many promising drug candidates never enter further
development because of solubility problems.
Currently, the most popular approach to dissolve poorly soluble drugs and prepare
their dosage forms with sufficiently high bioavailability is the use of micellar drug
carriers, specifically polymeric micelles.
In this study LbL coating technology is proposed to make stable aqueous colloids
of poorly soluble drugs with high stability, controllable release (faster or slower than bulk
drug powders), and a very high content of the active drug. To achieve this, aqueous
suspensions of poorly soluble drugs with micron range particles are subjected to a
powerful ultrasonic treatment in order to decrease the size of individual drug particles to
the nano level (between 100 and 200 nm), and while still keeping the obtained
nanoparticles under sonication to prevent their fast agglomeration, they are stabilized in
solution by applying the LbL technology (alternating addition of polycations and
polyanions to the system) and assembling a thin polyelectrolyte coating on their surface.
In the process of assembly, the highly charged polymeric layers are always present on the
drug particle surface thus preventing particle aggregation after stopping the sonication. At
the end of the process, stable nanocolloidal dispersions are formed. After the first
polycation layer is deposited on the surface of a drug nanoparticle, it is stabilized by the
addition of following oppositely charged polyanion. They form a stable electrostatic
complex resulting in the appearance of a very thin but stable polymeric shell around each
drug nanoparticle. This polyelectrolyte multilayer shell prevents particle aggregation, and

V

can be easily and reproducibly formed on the surface of any drug particle. By varying the
charge density on each polymer or the number of coating cycles, particles with a different
surface charge and different composition of the polymeric coating can be prepared. This
provides a way to control drug release from such particles by designing the shell
architecture at the nanometer level. The use of a polymer containing reactive groups
(such as amino or carboxy-groups) for the last "outer" surface coating allow for the
attachment of specific ligands, or reporter groups, or other moieties of interest to the
nanoparticle surface.
By nanoencapsulation of such anticancer drugs as tamoxifen, paclitaxel, and
camptothecin, we demonstrate the general applicability of this approach. The final
content of the drug in the preparation as well as its release rate from the preparation can
be controlled by the multilayer composition of the shell. The process key point is the
deposition of the first polycation layer during the powerful sonication of the drug
dispersion. In this process, dispersed by the ultrasound fine drug nanoparticles are
immediately coated with a polyelectrolyte monolayer providing a high surface charge,
which prevents the aggregation. Such drug nanocolloids remain stable in aqueous
solutions after switching off the sonication.
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CHAPTER 1
INTRODUCTION
The objective of this research is to provide a universal and efficient platform for
making stable colloids of various poorly water-soluble drugs with a high concentration of
a drug in colloidal particles. Nanosized colloidal suspensions of poorly soluble drugs will
dramatically increase drug solubility and bioavailability. Colloidal particles can also be
easily made organ-specific (targeted) by modifying their surfaces with various specific
ligands, such as monoclonal antibodies [1].
Layer by layer technology can be applied to poorly soluble drug nanoparticles to
improve the solubilization and bioavailability by breaking them into stable colloids that
will have a high content of the active ingredient. Nanoparticles will be generated by
ultrasonication of the drug suspension. A polymeric coating, consisting of alternating
layers of differently charged soluble polymers, will prevent coated drug particles from
agglomeration. Drug content and release properties are to be controlled by the polymer
type and number of polymeric layers.
Need for an Ideal Therapeutic Agent
Many potent drugs and drug candidates, especially anticancer drugs, are poorly
soluble in water (e.g. tamoxifen, paclitaxel, camptothecin), which results in their low
bioavailability and difficulties in preparing dosage forms [2]. Optimal drug delivery and
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reduction of systemic adverse effects have been age old problems in chemotherapeutics
of human cancer. With the advent of the use of water insoluble cancer drugs like
paclitaxel and tamoxifen, it has been realized that better formulations are still needed for
more specific and controlled delivery of these agents. The desired features of
pharmaceutical carriers for parenteral (intravenous) administration include their small
size, biodegradability, high content drug in final preparation, prolonged circulation in the
blood, and, ideally, targeting required areas of interest passively (via enhanced
permeability and retention (EPR) effect) or actively (via specific ligands, such as
monoclonal antibodies) [1]. While these requirements are reasonably well met by a
variety of drug carriers (liposomes, microcapsules, nanoparticles) developed for watersoluble drugs, the development of nanoparticulate drug carriers displaying all of these
properties for the delivery of poorly soluble pharmaceuticals still represents a challenge
[3,4].
Mentioned below are some examples of insoluble chemotherapeutic agents:
1) Paclitaxel, a compound extracted from the bark of the Pacific yew tree, Taxus
brevifolia is a drug used in the treatment of lung, ovarian, and breast cancers and
advanced forms of Kaposi's sarcoma and acts by interfering with the normal
function of microtubule growth [5].
2) Tamoxifen is an oral selective estrogen receptor modulator (SERM) which is used
in breast cancer treatment, and is currently the world's largest selling breast cancer
treatment. Tamoxifen was invented by ICI Pharmaceuticals [5].
3) Camptothecin, a plant alkaloid from Camptotheca acuminate, demonstrated strong
antitumor activity against lung, ovarian, breast, pancreas, and stomach cancers by
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targeting intracellular topoisomerase I, a nuclear enzyme that reduces the
torsional stress of supercoiled DNA [6].
4) Meso-Tetraphenylporphine are porphyrins that are well known photosensitizing
agents, which induce photodamage to malignant tumors by producing singlet O2
via the energy transfer from the first triplet state of porphyrin to the ground triplet
state of molecular oxygen [7].
Low solubility in water, however, tends to be an intrinsic property of many drugs,
including the powerful anticancer agents mentioned above [2]. This is quite expected,
since the membrane permeability and efficacy of various drugs increase with increasing
hydrophobicity [2, 8, 9]. At the same time, intravenous administration of those
intrinsically hydrophobic agents can be associated with serious problems. One of them is
that the intravenous administration of relatively large aggregates/crystals of an insoluble
drug that is formed in an aqueous media may embolize blood capillaries and cause
unwanted effects, like tissue ischemia. Additionally, the low solubility of hydrophobic
drugs in combination with excretion and metabolic degradation often does not allow for
achieving therapeutically significant systemic concentrations. As a result, many
promising drug candidates never enter further development and do not result in
acceptable dosage forms because of solubility problems [3, 4].

Current Modalities of Developing an Ideal
Therapeutic Agent
Various attempts to solve the problem of solubilization of insoluble drugs are
associated with loading poorly soluble drugs (usually, hydrophobic molecules) into
various nanosized pharmaceutical carriers, such as liposomes (drugs are loaded into the
hydrophobic membrane of the liposome), micelles (drugs are loaded into the hydrophobic
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core of the micelle), and oil-in-water emulsions [10, 11]. Although, many experimental
data are available showing a dramatic increase in drug efficacy after loading into
nanocarriers (forming stable colloidal systems), the general problems associated with
these approaches include: relatively low loading efficacy of the drug into the nanocarrier
(between 0.5 and 25% by weight, usually below 10% wt); the impossibility of using the
same protocol for making solubilized forms of different drugs, since each drug requires
its own specific conditions for solubilization; difficulties with the scaling up the
technology; difficulties with controlling surface properties or surface composition of such
nanosystems; insufficient storage stability of such systems and their instability in the
body [11].
Currently, the most popular approach to solubilize poorly soluble drugs and
prepare their dosage forms with sufficiently high bioavailability is the use of micellar
drug carriers that is various polymeric micelles [12-16]. Micelles are colloidal particles,
usually spherical, with size in the nanometer range into which many amphiphilic
molecules self-assemble spontaneously. In an aqueous environment, hydrophobic
fragments of amphiphilic molecules form the core of a micelle, which is segregated from
the environment by hydrophilic parts of the molecules forming the micelle corona. The
hydrophobic core of micelles may be used as a cargo space for encapsulation of a variety
of sparingly soluble therapeutic and diagnostic agents. Such encapsulation substantially
increases the bioavailability of pharmaceuticals, protects them from destructive factors
upon parenteral administration, and beneficially modifies their pharmacokinetics and
biodistribution including the target accumulation via the EPR effect [17, 18].
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However, there exists a set of serious problems associated with micellar carriers,
which include low loading efficacy of the drug into the micelles (usually well below 5%
wt); the impossibility to use the same protocol for making solubilized forms of different
drugs, since each drug requires its own specific conditions for solubilization; problems
with controlling the release rate of the drug from micelles; difficulties with the scaling up
the technology; insufficient storage stability of micelles and their frequent instability in
the body [11].
Our Approach Towards Developing an
Ideal Chemotherapeutic Agent
There exists an interesting approach to assemble polyelectrolyte multilayer shells
having wall thickness of few nanometers on various particles, including very small ones,
through a LbL assembly [19-21]. A LbL assembly is a nanoassembly technique based on
alternate adsorption of oppositely charged polyelectrolytes, nanoparticles and proteins
[22-24]. These polycation/polyanion multilayers may have required composition with a
component location precision of one nanometer. An application of LbL assembly to tiny
solid cores allows for the formation of microcapsules. Among many other applications,
the formation of LbL polyelectrolyte capsules was used to prepare sustained release
formulation of some water-soluble drugs, such as ibuprofen, furosemide, nifedipine, and
insulin [25, 26]. These resulted in drug carrying microparticles, where coating with 4-5
polycation/polyanion bilayers allowed for reaching 3-4 hrs release of the drugs normally
completely dissolving in 1-2 minutes.
During the last several years, it was clearly demonstrated, that the passive
accumulation of drug carriers in the areas with leaky vasculature, such as tumors,
depends on the "physiological" properties of each particular cancer, tumor vasculature
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cut-off size being the most important parameter controlling penetration of drugs and drug
carriers through the endothelium and into the interstitium. In particular, it was shown that
different tumors possess different vascular permeability and, in certain cases, this
permeability can be rather low (small cut-off size of 200 nm or less), which prevents
many drug carriers from accumulation in tumors, such as Lewis lung carcinoma [18].
One should expect that LbL nanocolloids of poorly soluble drugs, being sufficiently
small in size, can also provide an efficient way of drug delivery in such areas. Here, we
suggest a novel application for the LbL coating technology to make stable aqueous
colloids of poorly soluble drugs with high stability, controllable release rate, and a very
high content of the active drug.

Layer by Layer Assembly
The assembly of organized macromolecular and nanoparticle has become
increasingly important. The methods used for the assembly of ultrathin films with various
degrees of molecular order and stability include: spin coating and solution casting,
thermal deposition, polyion LbL assembly, chemical self-assembly, Langmuir-Blodgett
technique and free-standing films (in this paper we will not discuss the methods of
inorganic film growth). The optimal combination of molecular order and stability of films
determines the practical usefulness of these technologies [27].
The most ordered macromolecular films are free-standing liquid crystalline films,
but they are very unstable. Langmuir-Blodgett (LB) method allows one to construct
amphiphile multilayers with a thickness ranging from 5 to 500 nm, however it does not
have any industrial applications, because only small, flat substrates can be covered by an
LB-film, and it produces intrinsic defects at the lipid grain borders [28-30]. Another

7
method that can be applied to surface modification (especially in biomaterials) is
monolayer self-assembly, based on thiol or silane compounds. By this method, one can
achieve self-assembly of 2-5 nm thick monolayers on silicon or gold surfaces, but there is
no simple means for constructing thicker films using this approach [31-33]. Other widely
used methods for the industrial manufacture of thin films are spin coating and thermal
deposition of macromolecules onto a substrate. Unfortunately, unlike the methods
considered above, these methods do not allow one to control the molecular order in the
films.
Finally, there is yet a newer method for film self-assembly that makes use of the
alternate adsorption of oppositely charged macromolecules (polymers, nanoparticles and
proteins) [21, 34-37]. The assembly of alternating layers of oppositely charged linear or
branched polyions and nanoparticles is simple and provides the means to form 5 -500 nm
thick films with monolayers of various substances growing in a pre-set sequence on any
substrate at a growth step of about 1 nm. These films have a lower molecular order than
LB or free-standing films but they have the advantage of high strength and easy
preparation. T. Mallouk [30] has called this technique "molecular beaker epitaxy,"
meaning that, with simple instruments and thus exploiting the materials self-assembly
tendency, one can produce molecularly organized films similar to the ones obtained for
metals and semiconductors using highly sophisticated and expensive molecular beam
epitaxy technology.
General Procedure
A cleaned substrate of any shape and dimension is immersed into a dilute solution
of a cationic polyelectrolyte, for a time optimized for the adsorption of a single
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monolayer (ca 1 ran thick), and then it is rinsed and dried. The next step is the immersion
of the polycation-covered substrate into a dilute dispersion of polyanions or negatively
charged nanoparticles (or any other nanosize charged species) also for a time optimized
for the adsorption of a monolayer, then rinsed and dried. These operations complete the
self-assembly of a polyelectrolyte monolayer and monoparticulate layer sandwich unit
onto the substrate (Figure 1.1). Subsequent sandwich units are self-assembled
analogously. Linear polycation / polyanion multilayers can be assembled by similar
means. Different nanoparticles, enzymes and polyions may be assembled in a preplanned order in a single film [22].
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Figure 1.1 Schematic showing the concept of electrostatic LbL assembly.
Standard Assembly Procedure
As a standard approach to film preparation we employ the following steps: 1)
Take aqueous solutions of polyion, nanoparticles or protein at a concentration of 0.1 - 1
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mg/mL and adjust the pH in such a way that the components are oppositely charged 2)
Take a substrate carrying a surface charge (e.g., plates or polymer films covered by a
layer of cationic poly(ethylenimine) which may be readily attached to many surfaces) 3)
Carry out alternate immersion of the substrate in the component's solutions for 10
minute with 1 minute intermediate water rinsing. To rinse a sample use a solution with
pH that keeps the polyions ionized 4) Dry the sample using a stream of nitrogen (note:
drying may hinder the assembly process, and it is not necessary for the procedure) [22].
Polyions predominately used in the assembly (Figure 1.2) are as follows:
polycations - poly(ethylenimine) (PEI), poly(dimethyldiallylammonium
(PDDA),

poly(allylamine)

poly(styrenesulfonate) (PSS),

(PAH),

polylysine,

chitosan;

chloride)

polyanions

poly(vinylsulfate), poly(acrylic acid), dextran sulfate,

sodium alginate, heparin, DNA . One can grow polymer nanocomposite films by means
of the sequential adsorption of different material monolayers that employ hundreds of
commercially available polyions. The only requirement is that there be a proper (positive
/ negative) alternation of the component charges [23].
We suggest using the LBL coating technology to make stable colloids of poorly
soluble drugs. For this purpose, the aqueous suspensions of poorly soluble drugs with
particle size of the order of microns are subjected to physical treatment, such as an
ultrasonic treatment, to decrease the size of individual particles to the nanolevel (between
50 and 1000 nm, preferably, between 100 and 200 nm), and then are stabilized in solution
by the formation of the thin polymeric layer on their surface. This polymeric layer
prevents particle agglomeration after stopping the physical treatment, which results in the
formation of stable colloidal dispersions with high drug content in each colloidal particle
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(more than 50% wt and up to 90% wt). The polymeric coating is formed based on the
polyelectrolyte complexing process, when, for example drug nanosuspensions formed by
ultrasonications are incubated in the presence of a watersoluble biocompatible polymer
(polycation or polyanion) to allow for its deposition on their surfaces. After that, the first
polymeric layer is stabilized by the addition of another, oppositely charged
polyelectrolyte, which forms a firm electrostatic complex with the first one resulting in
the appearance of a very thin but extremely stable polymeric shell around each drug
nanoparticle. This shell prevents particle agglomeration, and can be easily and
reproducibly formed on the surface of any drug particle. By varying the charge density on
each polymer, or the number of coating cycles, drug particles can be prepared with a
different surface charge and different thickness of the polymeric coat. This, in turn,
provides an easy way to control drug release from such particles. In addition, used
polymers can also incorporate reactive groups allowing for further attachment of various
specific ligands or reporter groups or other moieties to their surface. These moieties can
also be incorporated into the polymeric shell during its formation of the drug
nanoparticle.
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Figure 1.2 Polyion's structural formulas.

CHAPTER 2
INSTRUMENTS AND METHODS
Ultra Sonicator
A MISONOX S 3000 power sonicator was used for all the nanoparticle suspension
formation experiments prior to LbL. The drug was subjected to very high sonication
energy, up to 18 W via the sonicator probe, as shown in Figure 2.1. For all sterile sample
preparations for animal studies, the sonicator tip could be detached and autoclaved.
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Figure 2.1 MISONOX S 3000 power sonicator.
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Ultracentrifugation Machine
An Eppendorf Centrifuge 5804 R machine, Figure 2.2, was used to carry out all
the Layer by Layer assembly nanoparticle separation and polyelectrolyte washing
steps. This machine was able to provide centrifugation speeds upto 15000 rpm and
the enviournment temperature could be controlled down to zero degrees centigrade,
although for our experiments usually speeds up to 11000 rpm for 7-10 minutes were
sufficient to separate nanoparticles from the colloidal suspension.

Figure 2.2 Eppendorf centrifuge 5804 R machine.
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Zeta Potential Meter
A ZetaPlus Brookhaven microelectrophorectic instrument, Figure 2.3, was used
to measure the surface charge on nanoparticles and the hydrodynamic diameter.
Either buffer or water was used as a medium for the colloidal suspension of drug
nanoparticles.

Figure 2.3 ZetaPlus Brookhaven microelectrophorectic instrument.
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Confocal Microscopy
Lieca TCS SP2 laser scanning confocal microscope, Figure 2.4 was used to
visualize the morphology of colloidal drug particles and for the proof that the
polyelectrolyte layer is being assembled over the drug particles by direct visualization
of the FITC labeled PAH. Although only particle sizes >= 1 micron in size could be
viasualized in detailed morphology, nanoparticles upto 100 nano meters were also
visualized as tiny dots without much detailed morphology. These results were needed
before proceeding with further experiments and Electron Microscopy Imaging.

Figure 2.4 Lieca laser scanning microscope.
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Scanning Electron Microscopy
A Hitachi S 4800 Scanning Electron Microscope, Figure 2.5, was used for the most
detailed morphology and characterization of the formed drug nanoparticles. Drug
particles as small as 100 nanometers or less were very conveniently visualized and
measured with this microscope. Bare silicon substrates were used to make diluted
samples of the drug nanoparticles into templates for visualization. The samples were not
heat dried but allowed to dry overnight at room temperature.

Figure 2.5 Hitachi S 4800 Scanning Electron Microscope.
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Ultra Violet Spectrophotometry
An Aligent 8453 UV- Vis Spectrophotometer, Figure 2.6, was used to calculate
standard curves for all the drug release pharmacodynamic diffusion experiments through
a 200 nanometer nitrocellulose membrane in a horizontal diffusion chamber. The peak
was observed at 240 nm for both Paclitaxel and Tamoxifen.

Figure 2.6 Aligent 8453 UV- Vis Spectrophotometer.

CHAPTER 3
STABLE NANOCOLLOIDAL DRUG FORMULATION
USING SYNTHETIC POLYELECTROLYTES
Stable nanocolloids of insoluble drugs with very high drug content (up to 90% wt)
can be easily and reproducibly prepared through the application of the LbL technology,
the alternate adsorption of oppositely charged polyelectrolytes on the surface of drug
nanoparticles produced by ultrasonication of larger drug crystals. Such polymeric coating
prevents drug nanoparticle aggregation and creates a firm polymeric shell on their
surfaces [21]. Drug release rate from such nanocolloidal particles can be easily controlled
by assembling multilayer shells with variable shell density and thickness. Various
additional functions, such as specific targeting ligands, can be easily attached to the
surface on nanocolloidal particles of poorly soluble drugs by using a polymer with free
reactive groups for the "outer" coating. This may represent a novel approach to preparing
convenient dosage forms of poorly soluble drugs [38].
Here, we demonstrate a novel application for the LbL coating technology to make
stable aqueous nanocolloids of poorly soluble drugs with a very high content of the active
drug and a controllable drug release rate [39]. To achieve this, aqueous suspensions of
these drugs with micron range particles are subjected to the ultrasonic treatment in order
to decrease the size of individual drug particles to the nano level (between 100 and 200
nm) and, while still keeping the nanoparticles formed under the sonication to
18
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prevent their fast agglomeration, stabilize them in solution by applying the LbL coating
method (alternating addition of polycations and polyanions to the system) and assembling
a thin polyelectrolyte shells on their surfaces (Figure 3.1 ). In the process of the assembly,
the highly charged polymeric layer is formed on the drug particle surface already after the
first polymer application, and this layer prevents drug particle aggregation after
terminating the sonication. At the end of the process, stable coated nanocolloidal drug
dispersions are formed with high drug content in each particle (more than 50% wt and up
to 90% wt).

/. Formation of colloidal nanoparticles
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Figure 3.1 Principal scheme of nanocolloidal particles formation using LbL from low
solubility drugs.
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LbL assembly can utilize a broad variety of polyiones, including many
biocompatible ones. Polycations can be represented by poly(ethyleneimine) (PEI),
poly(allylamine) (PAA), polylysine, chitosan, gelatin B, amino-dextran, protamine
sulfate; polyanions - by poly(styrene sulfonate) (PSS),

poly(acrylic acid), dextran

sulfate, carboxymethyl cellulose, sodium alginate, hyaluronic acid, gelatin A, chondroitin
and heparin. After, for example, the first polycation layer is deposited on the surface of
the drug nanoparticle; it is followed by the addition of an oppositely charged polyanion
and results in formation of a stable interpolyelectrolyte complex shell (3-30 nm) around
each drug nanoparticle. This polyelectrolyte multilayer shell can be easily and
reproducibly formed on the surface of any drug particle. By varying the charge density on
each polymer or the number of coating cycles, particles with a different surface charge
and different composition of the polymeric coat can be prepared. This provides a way to
control drug release from such particles by designing the shell architecture at the
nanometer level. The use of a polymer containing reactive group (such as an amino or
carboxylic group) for the last "outer" surface layer will allow for the attachment of
specific ligands, or reporter groups, and other moieties of interest to drug nanoparticles
(see example in Figure 3.2) [40].
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Figure 3.2 Schematics of the conjugation of an antibody (or any other ligand) to the LbL
paclitaxel nanoparticles via free amino-groups of the "outer" polymeric layer.

We present here the results of our studies on using the LbL assembly for the
preparation of stable nanocolloids of poorly soluble drugs with very high drug content.
By nanoencapsulation of such anticancer drugs as tamoxifen and paclitaxel, we
demonstrate the general applicability of this approach to prepare non-targeted and
targeted drug nanoparticles with very high drug content and controlled drug release rate.
Materials and Methods
Poorly soluble and potent anti-cancer drugs tamoxifen (TMF) and paclitaxel
(PCT) have been used for our experiments (solubility below 1 ug/mL). The
polyelectrolytes used for the LbL assembly included positively charged poly(allylamine
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hydrochloride) (PAH), FITC-labeled PAH, and poly(dimethyldiallylamide ammonium
chloride) (PDDA); all at the concentration of 2 mg/mL; and negatively charged sodium
poly(styrene sulphonate) (PSS); also at the concentration of 2 mg/mL. Deionized water
and PBS, pH 7.4, were used as the solvents. Ultra Sonicator 3000 (Misonix Inc,
Farmingdale NY) was used for drug crystals disintegration at the power of 3 - 18 W and
sonication time of 10-30 minute. To prevent sample overheating during the sonication
and to keep the temperature in the range of 20-30°C, liquid nitrogen was used to cool the
sample tubes liquid nitrogen was used. A quartz Crystal Microbalance (9 MHz QCM,
USI-System, Japan) was used to measure the thickness of the polyelectrolyte multilayer.
Surface potential (zeta potential) and particle size measurements were performed using
the ZetaPlus Microelectrophoresis (Brookhaven Instruments). Field Emission Scanning
Electron Microscope (Hitachi, S-4800) was used for particle imaging. Laser Scanning
Confocal Microscope, Leica TCS SP2 (Leica Microsystems Inc) was also used to control
the shell formation and to follow the colloid stability.

LbL Assembly and Some Properties of Nanocolloids
Initially, for disintegration, all drug samples were ultra sonicated with cooling at
18 W for up to 30 minutes in 1 mL volume before any polyelectrolyte was added. The
size of the drug particles formed was periodically measured. Prior to the addition of the
first layer of polyelectrolyte, the zeta potential reading was also taken. Polycations were
used to form the first surface layer, since drug nanoparticles of both drugs were found to
bear the intrinsic negative charge. Drug samples were then centrifuged at 14,000 rpm for
7 minute, washed and re-suspended in water or PBS to remove the excess polyelectrolyte
before further zeta potential readings were taken. Then, the coating process was repeated
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without the ultrasound applied and with the use of the oppositely charged polymer
(polyanion, in this case). Zeta potential measurements were taken after each next layer
addition. The images of colloidal particles formed were normally taken immediately and
48 hrs after the LbL assembly was completed to check for the stability of the colloids
formed. Dry samples were prepared for SEM imaging using 5-10 uL of the colloidal
suspension obtained. Sample droplets on bare silicon wafers were dried by heating them
at 50°C for 1 hr or, by keeping overnight at room temperature. Drug colloids were kept in
a low volume of saturated solution to prevent drug release.

Drug Release from Colloidal Particles at
Sink Conditions
To study the release rate of different drugs from the colloidal particles prepared
using the LbL assembly, the samples prepared using a different number of coating cycles
were placed in 1 mL horizontal diffusion chambers made of cellulose acetate membrane
and stirred in a large volume of PBS, pH 7.2, to mimic sink conditions expected in vivo.
The concentration of the released drugs was measured by the HPLC.
Attachment of Ligand Moieties to the LbL
Nanocolloids of Poorly Soluble Drugs
To prepare nanocolloids with the "reactive" surface suitable for the covalent
attachment of various ligands to their surfaces, PAH containing free amino groups was
used to form the outer layer on the drug particles. Paclitaxel was used in this series of
experiments. To conjugate the monoclonal nucleosome-specific 2C5 antibody (mAb
2C5) for recognizing a broad variety of cancer cells via the cancer cell surface-bound
nucleosomes [41, 42], the reaction was carried out in two steps (Figure 3.2). In the first
step, the carboxylate groups on the mAb 2C5 were activated using l-ethyl-3-
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carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide (sulfo-NHS) to make
it amine-reactive. In the second step, the activated antibody was added to LbL paclitaxel
nanoparticles coated with polyamino-containing PAH polymer. All reactions were carried
out in HBS, pH 7.4 at 4°C with continuous stirring in presence of argon gas. The
modified particles were centrifuged at 12 rpm for 10 minute and re-suspended twice
using PBS to remove the unconjugated antibody.
The amount of paclitaxel in all the nanoparticle preparations was measured by the
reversed phase-HPLC. The particles were dissolved in the mobile phase prior to injecting
into the HPLC column. A D-7000 HPLC system equipped with a diode array (Hitachi,
Japan) and Spherisorb ODS2 column, 4.6mmx250mm (Waters, Milford, MA, USA) was
used. The column was eluted with acetonitrile/water (65:35%, v/v) at 1.0 mL/min.
Paclitaxel peak was detected at 227 nm. Injection volume was 50uL; all samples were
analyzed in triplicate.
Antibody Activity Preservation on the Surface of
LbL Drug Nanocolloid
To verify the preservation of mAb 2C5 specific activity after the conjugation with
LbL-paclitaxel nanoparticles, a standard ELISA was performed. Briefly, ELISA plates
pretreated with 40 ug/mL polylysine solution in TBS, pH 7.4, were coated with 50 uL of
40ug/mL nucleosomes (the water-soluble fraction of calf thymus nucleohistone,
Worthington Biochemical, Lakewood, NJ) and incubated for 1 h at room temperature.
The plates were rinsed with 0.2% casein, 0.05% Tween 20 in TBS (casein/ TBS), pH 7.4.
To these plates, serial dilutions of mAb 2C5-containing samples were added and
incubated for 1 hr at room temperature. The plates were extensively washed with
casein/TBS and coated with horseradish peroxidase goat antimouse IgG conjugate (ICN
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Biomedical, Aurora, OH) diluted according to the manufacturer's recommendation. After
1 h incubation at room temperature, the plates were washed with casein/TBS. Bound
peroxidase was quantified by the degradation of its substrate, diaminobenzidine supplied
as a ready-for-use solution, Enhanced K-Blue TMB substrate (Neogen, Lexington, KY).
The intensity of the color developed was analyzed using an ELISA reader at the
wavelength of 492 nm, Labsystems Multiscan MCC/340 (Labsystems and Life Sciences
International, UK).
Cytotoxicty of Targeted Paclitaxel LbL Nanocolloid
The cytotoxicity of various concentrations of LbL-paclitaxel nanoparticles against
and MCF-7 and BT-20 cells was studied using an MTT test. A ready-for-use CellTiter
96® Aqueous One solution of MTT (Promega, Madison, WI) was used according to a
protocol suggested by the manufacturer. Formulations with paclitaxel concentration of up
to 200 ng/mL dispersed in Hanks' buffer were added to cells grown in 96-well plates to
about 40% confluence. After 48 hr or 72 hr of incubation at 37°C, 5% CO2, plates were
washed three times with Hanks' buffer followed by the addition of 100 p.L of media and
20 uL of CellTiter 96® Aqueous One solution. After 1 hr of incubation at 37°C, 5% C0 2 ,
the cell survival rate was estimated by measuring the color intensity of the MTT
degradation product at 492 nm using an ELISA plate reader. Untreated cells were
considered as 100% growth.
Results
LbL-Stabilized Drug Nanocolloids
and Surface Zeta Potential
To find the optimal sonication condition, we have performed our initial
experiments with tamoxifen crystals at a drug concentration in the suspension of 2
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mg/mL. Figure 3.3 clearly shows that particle size expectedly and strongly depends on
the sonication time. After 30 minutes of sonication at 18 W, particles with the size of
about 100 nm were obtained (with the addition of polycationic PDDA prior to the size
measurement to prevent particle re-aggregation). When similar sonication conditions
were applied to paclitaxel, particle sizes of about 100 nm were also obtained. Further
increase in the sonication time did not result in a significant decrease in drug particle size.
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Figure 3.3 The dependence of drug particle size on the duration of sonication.
In experiments with tamoxifen and paclitaxel nanocrystals (2 mg/mL), PAH was
present in solution for the first polymeric monolayer on the particle surface and prevents
particle aggregation after the removal of ultrasound. Figure 3.4 gives values of the zeta
potential during the process of sequential polycation/polyanion adsorption on tamoxifen
cores. After the addition of the PDDA polycation to the initially negatively charged
tamoxifen particles under sonication, drug nanoparticles are recharged to the positive
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potential of ca. +45 mV and form stable colloidal solution when the sonication is
terminated. Then, we proceeded with the LbL assembly on tamoxifen nanoparticles
through the PSS polyanion adsorption adding one more monolayer to the shell, and again
reversed the surface potential to the negative value of -17 mV. By adding the PDDA
polycation again, we again made tamoxifen particles positively charged at ca. +80 mV.
The fourth polymer layer (negative PSS this time) made the tamoxifen particles negative
again, and so on. At the end, we obtained tamoxifen nanoparticles coated with an
organized multilayer shell with the composition (PDDA/PSS)3.
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Figure 3.4 Changes in drug particle zeta potential during the process of the LbL
assembly. LbL assembly of tamoxifen (2 mg/mL) resulting in the product coated with
three bilayers composed of PDDA and PSS.
In Figure 3.5, similar changes in zeta potential values are demonstrated during the
LbL shell assembly process for paclitaxel. Again, we have initially negatively charged
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bare drag nanoparticles which, after the sonication with the addition of another
polycation (PAH), became positive and formed stable colloids. Further assembly with the
corresponding changes in zeta potential values allowed for the formation of the final shell
with (PAH/PS S)2 composition.
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Figure 3.5 LbL assembly of paclitaxel (4 mg/mL) resulting in the product coated with
two bilayers composed of PAH and PSS.
In separate experiments with quartz Crystal Microbalance (QCM) monitoring of
the PDDA/PSS or PAH/PSS assembly on a quartz resonator, we found that a single
polycation/polyanion bilayer has a thickness of 1.5 nm in the dry state. Polyelectrolyte
multilayer thickness doubles in water [39]. Therefore, one could estimate our
(PDDA/PSS)3 shell thickness as ca. 4.5 nm in the dry state and 9 nm in an aqueous
solution, and (PAH/PSS)2 shell thickness as ca. 3 nm in the dry state and 6 nm in water.
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Nanoparticle Imaging and Some Properties
The particle size of all the drug samples formulated by the LbL technology into
nanocolloidal state was confirmed by scanning electron microscopy and confocal
fluorescent microscopy. Figure 3.6 shows SEM images of prepared colloidal tamoxifen
particles. Particles of tamoxifen have mainly a spherical shape and have a diameter of
120 ± 30 nm. LbL-coated paclitaxel has the elongated rod-like shape with approximate
measurements of 50 x 120 nm.
The samples were rinsed with deionized water to get rid of the extra polyelectrolyte
and luL of the sample that was dried on a bare silicon wafer at room temperature for 12
hrs was used for SEM imaging. The samples were not sputtered prior to the imaging. The
silicon wafer with the samples was mounted on a metal stub with an adhesive. During
the drying process the nanoparticles become partially aggregated, as can be seen in the
Figure 3.7a. To prove that this aggregation is the result of SEM sample preparation and
does not proceed in aqueous suspension, we made fluorescence confocal images of our
samples. With this in mind, we have used FITC-labeled PAH to prepare LbL-coated drug
particles following same protocol as for the samples shown on Figure 3.6 a-b. Figure 3.8,
showing the fluorescence image of LbL-coated tamoxifen particles in suspension, does
not reveal any aggregation. One can see multiple individual fluorescent green dots (the
color is due to FITC labeling), although the confocal microscope resolution of ca. 100 nm
does not allow for seeing the detailed structure of individual nanocapsules.
Taking into account that the thickness of a single polymeric layer is approx. 1.5 nm
in the dry state, we can easily calculate that the drug content in stable nanocolloidal
particles of poorly soluble drugs is from 85 % wt (in case of tamoxifen particles with a
triple bilayer coating) to approx. 90% wt (in case of paclitaxel particles with a double
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layer coating), which is dramatically higher than that for any other solubilization method.
Colloidal suspensions of both drugs are completely stable during the two weeks of
observation.

b)

Figure 3.6 SEM images: (a-c) tamoxifen nanoparticles of ca. 120 nm after 30 minute
sonication in the presence of 2 mg/mL PAH.
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Figure 3.7 SEM images: (a-b) paclitaxel nanoparticles after 30 minute sonication and
assembly of the LbL coating with (PAH-PSS)2 composition.
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Figure 3.8 Confocal fluorescent image of an aqueous dispersion of LbL tamoxifen
nanocolloid coated with FITC-labeled PAH.
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Drug Release from LbL Nanocolloids
LbL technology allows for the easy control of the drug release rate from polymerstabilized colloidal nanoparticles by simple changes of coating thickness or composition.
Figure 3.9 presents the release curves for tamoxifen with different coating thickness in
standard sink conditions at the same drug concentration of 2 mg/mL using the Peppas
model (exponential approximation) [43]. As one could expect, we observe a slower
release rate as the number of polyelectrolyte layers in the shell increases. At sink
conditions, non-coated tamoxifen crystals (both without and with sonication) solubilize
within approx. 2 hr, while LbL coating allows for easily extending this time to approx. 10
hr (extrapolation). Similar results were also obtained for paclitaxel (data not shown).
Clearly, slower release rates are also possible depending on the architecture of the LbL
coating.
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Figure 3.9 Controlled release of tamoxifen from the LbL nanocolloidal partricles.
Shown in Figure 3.9 are dissolution rates of free tamoxifen as drug crystals
without sonication - 1, and nanoparticles of sonicated non-coated drug - 2 and tamoxifen
release form the ca. 125 nm LbL nanocolloidal particles with different coating
composition: PDDA coating - 3, and (PDDA/PSS)3 coating - 4, at sink conditions in
PBS buffer at pH 7.4.
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Surface Modification of LbL Coated Drug Nanoparticles
To confirm that LbL-coated drug nanoparticles can be easily derivatized on the
surface in order to impart them various additional properties including targetability, we
have attached tumor-specific mAb 2C5 to the paclitaxel nanoparticles via free amino
groups belonging to the surface layer of PAH.
ELISA with the nucleosome monolayer (specific antigen for mAb 2C5), the results
of which are presented in Figure 3.10, clearly confirms that 2C5-modified LbL-coated
paclitaxel nanoparticles acquire the ability to specifically recognize the target antigen, i.e.
become targeted.
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Figure 3.10 ELISA for 2C5-LbL paclitaxel immuno-nanoparticles (the values are average
±SD).

CHAPTER 4
PACLITAXEL AND TAMOXIFEN NANOPARTICLE LbL WITH
BIOCOMPATIBLE COATINGS
Drug nanoparticle stabilization by LbL procedure using synthetic polyelectrolyte
was first established [39], and then it was transferred to biocompatible polymers, such as
cationic: polylysine, protamine sulphate and anionic: dextran sulfate, and bovine serum
albumin (Figure 4.1) [44]. This was needed for in-vivo use of the drug nanoparticles to
prevent any anaphylactic reactions in amimals [45]. Just as in previous experiments, the
first polycation layer is deposited on the surface of the drug nanoparticle, and is then
followed by the addition of an oppositely charged polyanion which results in the
formation of a stable inter-polyelectrolyte complex shell around each drug nanoparticle.
By varying the charge density of each polymer or the number of coating cycles, particles
with a different surface charge and different composition can be prepared. The use of a
polymer containing reactive groups (such as amino groups) for the last "outer" surface
layer allows for the attachment of specific ligands and other moieties of interest to drug
nanoparticles. We present here a proprietary method (Nemucore Medical Innovations
Inc., Boston) of sonicated LbL assembly for the preparation of stable nanocolloids of
paclitaxel and tamoxifen with very high drug content.
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Figure 4.1 Biocompatible polyelectrolytes for in-vivo application.

Materials and Methods
Poorly soluble and potent anti-cancer drugs paclitaxel and tamoxifen have been
used. The polyelectrolyte

used

included

positively

charged

polylysine, poly

(dimethyldiallyl ammonium chloride) (PDDA), protamine sulphate (PS); and negatively
charged sodium poly (styrene sulphonate) (PSS) and bovine serum albumin (BSA).
Ultrasonicator 3000 (Misonix Inc) was used for drug crystals disintegration at a power of
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18 W. To prevent sample overheating during the sonication and to keep the temperature
in the range of 20-25°C, liquid nitrogen was used to cool the sample tubes.
For disintegration, all drug samples were ultra sonicated with cooling for 10
minutes before polyelectrolyte was added. After the polyelectrolyte was added, the
samples were sonicated for another 20 minutes. Polycations were used to form the first
surface layer, since drug nanoparticles were found to bear an intrinsic negative charge.
Drug samples were then centrifuged washed and re-suspended in PBS buffer to get rid of
the excessive polycation before further zeta potential readings were taken. Then, the
coating process was repeated with polyanion, followed by polycations, and so on. The
resulting high concentration drug colloids were kept in a low volume of saturated
solution to prevent drug release. To study the release rate of drugs from the colloidal
particles, the samples were placed in horizontal diffusion chambers made of cellulose
acetate membrane and stirred in a large volume of PBS, pH 7.2, to mimic the sink
conditions expected in-vivo.

Attachment of Ligand Moieties to the LbL
Nanocolloids of Poorly Soluble Drugs
To prepare nanocolloids with the "reactive" surface suitable for the covalent
attachment of various ligands to their surface, polycation containing free amino groups
was used to form the outer layer on the drug nanoparticles. To conjugate the monoclonal
nucleosome-specific 2C5 antibody (mAb 2C5) for recognizing a broad variety of cancer
cells [41, 42], the reaction was carried out in 2 steps. In the first step, the carboxylate
groups on the mAb 2C5 were activated using l-ethyl-3-carbodiimide hydrochloride
(EDC) and N-hydroxysulfosuccinimide (sulfo-NHS) to make it amine-reactive. In the
second step, the activated antibody was added to LbL paclitaxel nanoparticles coated
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with polyamino-containing polymer. To verify the preservation of mAb 2C5 specific
activity after the conjugation with LbL-paclitaxel nanoparticles, a standard ELISA was
performed. The cytotoxicity of various concentrations of LbL-paclitaxel nanoparticles
against MCF-7 and BT-20 cells was studied using an MTT test.
Results and Discussion
After 30 minutes of LbL assisted sonication, paclitaxel particle sizes of about 50 x
50 x 120 nm were obtained (Figure 4.2). Further increase in the sonication time did not
result in a significant decrease in drug particle size. Initially we have initially negatively
charged bare drug nanoparticles, which after the sonication with the addition of cationic
polylysine or protamine sulphate became positive and formed stable colloids. Further
assembly with the corresponding changes in zeta potential values allowed formation of
the two bilayer shell with biocompatible protamine sulfate and albumin: (PS/BSA) 2.

(a)

(b)

(c)

Figure 4.2 SEM images (Hitachi-S4800) of LbL encapsulated drug nanoparticles.
Paclitaxel: (a) 20 minute sonication + LbL coating, (b) smaller concentration sample
with 30 minute sonication + LbL coating with protamine sulfate / albumin, size 50 x 50 x
120 nm, (c) 120 nm diameter tamoxifen particles prepared via sonication in the presence
of polylysine.
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Figure 4.3 gives values of the surface zeta potential during the process of sequential four
step protamine sulfate/ albumin adsorption on paclitaxel nanocores. The thickness of this
shell was estimated with a Quartz Crystal Microbalance as ca. 6 nm in dry state and 12
nm in water. Similar zeta potential alternation was observed during shell assembly on
tamoxifen nanoparticles.
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Figure 4.3 Changes on paclitaxel particle zeta potential in the process of the LbL coating
with two bilayers of protamine sulphate (PS) and bovine serum albumin (BSA).

Nanoparticle Imaging and Drug Release
The particle size of all the drug samples formulated by the LbL technology into
nanocolloidal state was confirmed by scanning electron microscopy and confocal
fluorescent microscopy (Figure 4.2). At 20 minute sonication, we obtained submicron
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particles, and further sonication with polycations and liquid nitrogen cooling resulted in
nanosized particles. LbL-coated paclitaxel has the elongated rod-like shape of
approximately 50 x 50 x 120 nm. Particles of tamoxifen demonstrate mainly spherical
shape and have a diameter of 120 ± 30 nm. The spherical shape of tamoxifen is probably
due to the melting and then solidifying of the drug nanoparticle during powerful
sonication (instantaneous local temperature during collapsing cavitations' microbubbles
reaches hundreds degrees). This was confirmed from the amorphous form of the resulting
Tamoxifen nanoparticles. The SEM images were obtained after drying the samples, and
during this process the nanoparticles become partially aggregated. This aggregation does
not proceed in aqueous suspension, as it was demonstrated with fluorescence confocal
images of our samples [39].
Taking into account that the thickness of a single polymeric layer is approx. 3 nm
in dry state, we can calculate that the drug content in stable nanocolloidal drug particles is
from 90 % wt (in case of paclitaxel particles with a double layer coating) to 85 % wt (in
case of tamoxifen particles with a triple bilayer coating) which is dramatically higher
than that for the case of other solubilization methods. Colloidal suspensions of both drugs
were stable during a month of observation.
LbL technology allows control of the drug release rate from polymer-stabilized
colloidal nanoparticles by simple changes of coating thickness or composition. As one
could expect, we observed a slower release rate as the number of polyelectrolyte layers in
the shell increases. At sink conditions, non-coated tamoxifen particles (after sonication)
dissolve within approx. 2 hr, while LbL coating allows the extension of this time to 10
hrs. Figure 4.4 gives the release curves for 2 mg/mL paclitaxel in PBS buffer at pH 7.2
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through a 0.2 micrometer pore nitrocellulose membrane. The upper most curves represent
the bare, uncoated micronized drug, and the two lower curves show the release from 125nm diameter nanoparticles coated with one PDDA monolayer and a thicker shell of three
bilayers of (PDD/PSS)3. Similar results were obtained also for tamoxifen. These are
initial release

experiments

done

with

synthetic polymers. Experiments

with

biocompatible shells of (protomine sulfate / albumin)3 gave similar release rates.

Figure 4.4 Release of paclitaxel nanoparticles at sink condition in PBS buffer at pH 7.2
after LbL-coating with PDDA and (PDDA-PSS)3 (lower two curves as compared to
uncoated drug nanoparticles in the upper curve).
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Surface Modification of LbL-Coated Drug Nanoparticles
To confirm that LbL-coated drug nanoparticles can be easily derivatized on the
surface in order to impart to them various additional properties, including targeted
delivery, we have attached tumor-specific mAb 2C5 to the paclitaxel nanoparticles via
free amino groups belonging to the outermost surface layer of PAH.
Increased Cytotoxicity of Tumor Cell-Targeted
LbL Drug Nanocolloids in vitro
Our preliminary in vitro experiments with MCF-7 and BT-20 cancer cell lines
clearly confirmed that targeted drug nanoparticles demonstrate higher cytotoxicity than
their non-targeted counterparts. At a paclitaxel concentration of 100 ng/mL for the MCF7 cells (Figure 4.5) and 30 ng/mL for the BT-20 cells (Figure 4.6), when virtually no
cytotoxic effect can be observed with non-targeted LbL-coated paclitaxel nanoparticles
(around 95% of cancer cells remains alive after incubation for 48 or 72 hrs), 2C5-targeted
LbL-coated paclitaxel particles kill at least 30% of the cancer cells (Figure 4.7). These
results confirms that LbL technology allows for decorating the surface of stable colloidal
drug particles with a very high drug content with various additional functions as needed.

*
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Figure 4.5 Cytotoxic effects of different concentrations of paclitaxel in "Plain" LbLPaclitaxel nanoparticles and mAb2C5-LbL-Paclitaxel "immuno" nanoparticles on MCF-7
cells after 48 hrs of incubation with the formulations.
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CHAPTER 5
STABLE NANOPARTICLES OF GADOLINIUM
FOR MOLECUALR IMAGING
Gadopentate Dimeglumine
Many potent radio diagnostic drugs, like Gadolinium based MRI contrast agent
Gadopentate Dimeglumine, are associated with high incidence of toxicity and difficulties
in preparing dosage forms [46]. Making these substances to have better bioavailability
can simplify their administration, result in easier-to-make dosage forms, and minimize
their non-specific toxicity and side-effects upon their administration. It can also allow for
converting many known powerful but insoluble substances into clinically acceptable
drugs. In recent years, serious problems have arisen involving the use of gadolinium for
help with MRI's and MRA's in patients who have kidney problems or renal disease [47].
When gadolinium is injected into an otherwise-healthy patient, it is generally is
eliminated by the kidneys after the examination, and does not cause problems. However,
those with kidney problems are generally unable to expel the substance from their
systems, which results in prolonged exposure to the agent within their bodies. Prolonged
exposure to gadolinium can result in the development of Nephrogenic Systemic Fibrosis
(NSF), which is also known as Nephrogrenic Fibrosing Dermopathy (NFD) [47]. Only a
few studies involving nanometer sized gadolinium particles have been reported, which is
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mainly due to the challenges associated with fabricating a stable colloidal suspension of
gadolinium in an aqueous media [48, 49].
We elaborate on the use of the LbL polyelectrolyte coating technology to
fabricate and characterize new particulate contrast media, gadopentate dimeglumine
nanoparticles with biocompatible coating as prototype multimodal imaging and
therapeutic agents. For this purpose, the aqueous suspensions of Gadopentate
dimeglumine with particle size of the order of microns are subjected to unltrasonic
treatment to decrease the size of individual particles to the nanolevel (between 50 and
1000 nm, preferably, with size distribution maximum between 100 and 200 nm), and
then, with sonication treatment on, are stabilized in solution by the formation of the thin
polyelectrolyte layer on their surface. This charged polymeric layer, with zeta potential of
ca +15 mV, prevents particle agglomeration after stopping the physical treatment, which
results in the formation of stable colloidal dispersions with high drug content in each
colloidal particle (more than 50% wt and up to 90% wt). Further building of the shell
through additional alternate adsorption of polyanion (such as sodium polystyrene
sulfonate) and polycations (such as polyallylamine) allows formation of a thicker shell
with higher zeta potential of ca 30-40 mV.

Application of LbL Assembly on Gadolinium
The aqueous suspensions of Gadopentate dimeglumine with particle size of the
order of microns is subjected to physical treatment, such as unltrasonic treatment, to
decrease the size of individual particles to the nanolevel (between 50 and 1000 nm,
preferably, between 100 and 200 nm), and then are stabilized in solution by the formation
of a thin polymeric layer on their surface. This polymeric layer prevents particle
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agglomeration after stopping the physical treatment, which results in the formation of
stable colloidal dispersions with high contrast content in each colloidal particle (more
than 50% wt and up to 90% wt). The polymeric coating is formed based on the
polyelectrolyte complexing process, when gadolinium nanosuspensions formed by
ultrasonications are incubated in the presence of a watersoluble biocompatible polymer
(polycation or polyanion) to allow for its deposition on their surface. After that, the first
polymeric layer is stabilized by the addition of another, oppositely charged
polyelectrolyte, which forms a firm electrostatic complex with the first one resulting in
the appearance of a very thin but extremely stable polymeric shell around each contrast
nanoparticle. This shell prevents particle agglomeration, and can be easily and
reproducibly formed on the surface of any drug particle. By varying the charge density on
each polymer, or the number of coating cycles, gadolinium particles can be prepared with
a different surface charge and different thicknesses of the polymeric coat. This, in turn,
provides an easy way to control drug release from such particles. In addition, the
polymers used can also incorporate reactive groups allowing for further attachment of
various specific ligands or reporter groups or other moieties to their surfaces. These
moieties can also be incorporated into the polymeric shell during the formation of the
drug nanoparticle.

Fabrication of Gd-DTPA- Dimeglumine Nanoparticles
into a Stable Aqueous Solution
Reagents
1) Gd-DTPA-Dimeglumine- 469 mg/ml diluted in 10X Deionized H20 (from ViewGam).
2) Aqueous Solvent - DI water at pH 7.0
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3) PAH- poly(allylamine hydrochloride)
4) FITC attached to PAH for fluorescent imaging.
Instruments
1) Zeta Plus- zeta potential Instrumet by Brookhaven Corporation.
2) Scanning Electron Microscope (HITACHI S-4800)
3) Ultra Sonicator- MISONIX 3000 at 18 W power.
4) Leica TCS SP2 Laser Scanning Confocal Microscope.
Substrate used for SEM analysis was bare silicon plate with out plasma sputtered Au
coating.
Methods
A total 46.9 mg/ml of Gd-DTPA-Dimeglumine was taken in 1 ml buffer volume
and sonicated in the MISONIX SONICATOR -3000 for 7 minute. Zeta Readings are
taken after sonication and before mixing the PAH solution. The solution was then mixed
with 2mg/ml of PAH for 20 minute, and then centrifuged, washed two times with DI
water, Zeta measurements, taken again.
Powerful sonication in the presence of polycation PAH resulted in the Gd-DTPADimeglumine sub-micronizing with simultaneous coating, which prevented drug reaggregation.
Coating architecture: Gd-PAH provided stable colloids with diameter of 105 nm
±10% and enhanced surface charge (negative or positive will depend on the
polyelectrolyte at the outermost layer).

Results
Zeta Potential Measurements
A reversal of surface charge was seen as shown in Figure 5.1. Again an inverse
relation of particle size and sonication time was observed (Figure 5.2).
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Figure 5.1 Surface charge measurements of Gd-DTPA Dimeglumine before and after
nanofabrication. An average of seven readings were taken.
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Scanning Electron Microscopy Imaging
Untampered Gd-DTPA particles (Figure 5.3) were much larger than the
nanofabricated ones as shown in Figure 5.4 and Figure 5.5.
Gd-DTPA Dimeglumine Without
Fabrication or Sonication.

• t,vV

a)

b)

Figure 5.3 Scanning electron microscopy images of Gd-DTPA Dimeglumine without any
sonication or coating. Particle Size ranged from 8-20 urn (a) & (b).

Nanofabricated Gd-DTPA
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Figure 5.4 Scanning electron microscopy images of Gd-DTPA Dimeglumine (a) after
utra sonication at 18 W, for 7 minutes, in the presence of 2 mg/ml PAH, (b) particle size
ranges from 2-3 urn as seen on higher magnification.
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b)
Figure 5.5 Scanning electron microscopy images of Gd-DTPA Dimeglumine (a) after
utra sonication at 18 W, for 15 minutes, in the presence of 2 mg/ml PAH, (b) smallest
particle size attained was 105 nanometers as seen at higher magnification.

Confocal Imaging
Proof of LbL layer was demonstrated by confocal imaging (Figure 5.6).

a)

b)

Figure 5.6 (a) Confocal and (b) Transmission images of Gd-DTPA Dimeglumine after
utra sonication at 18 W, for 7 minutes, in the presence of 2 mg/ml PAH- FITC.
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Novel Features of Our Technology
1.

Stable nanocolloids of various poorly bioavailable drugs can be prepared
following the same procedure, i.e. the procedure is applicable to a broad variety of
toxic and poorly soluble pharmaceutical agents

2.

The properties of the polymeric coat (i.e. surface properties of drug particles) can
be easily controlled though LbL polycation / polyanion assembly, forming a shell
of the needed molecular composition and increased surface charge.

3.

The composition and the architecture of the particle surface (of the polymeric
shell) can be easily controlled, resulting in easy control over its biological
properties and making complexes of two different agents.
The purpose of this research is to provide a universal and efficient platform for

making stable colloids of gadopentate dimeglumine with a high concentration of the
agent in the colloidal particles. Nanosized colloidal suspensions of gadolinium will
dramatically increase its solubility, bioavailability, and golmerular Alteration through the
kidneys, thus reducing its half life and adverse effects on the patients even with
compromised renal function. Colloidal particles can also be easily made organ-specific
(targeted) by modifying their surfaces with various specific ligands, such as monoclonal
antibodies, etc., to increase their diagnostic/therapeutic potential.

CHAPTER 6
CONCLUSIONS AND DISCUSSION
In all the work explained above, we have clearly concluded the following:
1) Stable nanocolloids of insoluble drugs with very high drug content can be easily and
reproducibly prepared through the application of LbL technology, i.e. combination of
sonication and alternate adsorption of oppositely charged polyelectrolytes, resulting in
nanoparticles with the content of the drug far exceeding other known systems
2) Drug release rate from such nanocolloidal particles can be easily controlled by
assembling organized multilayer shells with required wall composition, density and
thickness;
3) Various additional functions, such as specific targeted ligands, can be easily attached
to the surface on nanocolloidal particles of poorly soluble drugs by using a polymer with
free reactive groups for the "outer" coating and preserve their specific properties upon the
attachment;
4) Since drugs are not modified in any way in the process of solubilization and release as
free drug molecules, there is no concern regarding any possible changes in drug activity
in vivo. However, to deliver a desired dose of a poorly soluble drug in the body, a very
small quantity of a polymer (polymeric carrier) is required compared with any other
protocols currently used for administration of poorly soluble pharmaceuticals, thus
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simplifying the administration procedure and decreasing the possibility of carrier-related
side-reactions. This may represent a promising approach to obtaining convenient dosage
forms of poorly soluble drugs.
To summarize, the following formulation technique was demonstrated:
1) All drugs used were formulated into stable colloids by powerful sonication with
polycation coating with resultant particle sizes ranging from 130 nanometers to 400
nanometers.
2) Effective LbL assembly was possible, at least up to two bilayers, providing the needed
shell multilayer architecture for adjustable release and for binding of antibodies to amine
groups in the outermost layer (i.e. polylysine) for targeted delivery.
3) A negative surface potential of-15, -25 mV was found for all four drugs after powerful
10 minute to 30 minute sonication.
4) As the sonication time and power (to 18 W per mL) were increased, the drug particle
size was reduced showing a time dependence of size with sonication.

In one

embodiment, polycation coating was applied to the samples simultaneously with
sonication to prevent re-aggregation.
5) Zeta potential readings show stable polycation coating with drug surface re-charging to
+ 20 mV. This positive surface charge keeps drugs in a stable colloid form and prevents
re-aggregation. After the drug was coated, the surface potential remained the same even
48 hrs later, which demonstrates stable coating.
6) Negatively charged polyelectrolyte PSS addition failed to form stable colloids of these
drugs. Drug nanoparticle re-aggregated to larger size. Therefore, coating drug
nanoparticles with oppositely charged polyelectrolyte is a condition of the process.
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7) Sonication at lower temperatures of 5-10° C (with surrounding ice or liquid nitrogen)
showed even smaller particle sizes were attained.
SEM and confocal images taken 2-7 days after the sample formation demonstrated the
stability of the drug aqueous nanocolloids.
8) Two-twelve hrs release at pH 7.2 can be observed for the drug nanocolloids depending
on the polyelectrolyte shell composition. A longer release is achievable with tighter
capsule walls. For long storage of the colloids without dissolution, certain pH conditions
with low solubility rate may be useful.
Commercial Applications and Future Work
We have presented here a proprietary method (Nemucore Medical Innovations
Inc., Boston) of sonicated LbL assembly for the preparation of stable nanocolloids of
paclitaxel and tamoxifen with very high drug content.
Since many currently used "good" drugs have difficult to deal with dosage forms
and many potentially good drug candidates never enter further development because of
their low solubility and thus bioavailability and impossibility to make an acceptable
dosage form. The use of the suggested approach can eliminate these problems.
We await Phase I clinical trials of our nanoformulation, specially the cancer drugs
paclitaxel and tamoxifen once the pre-clinical, in vivo studies are completed.

APPENDIX
COMMERCIAL VIABILITY AND
SUMMARY OF RESULTS
Cross-Reference to Related Applications
This application claims the benefit of priority to U.S. Provisional Patent
Application No. 60/959,728, filed July 16, 2007, in collaboration with Northeastern
University in Boston, the contents of which are incorporated by reference herein in their
entirety.
Field of the Invention
The invention is in the field of therapeutic nanoparticles for medical screening
and treatment.
Background of the Invention
Many potent drugs and drug candidates, especially anticancer drugs, are poorly
soluble in water (e.g., tamoxifen, paclitaxel, and camptothecin). Their poor solubility
results in their low bioavailability and difficulties in preparing dosage forms.
Current attempts to solve this problem are associated with loading poorly soluble
drugs (usually hydrophobic molecules) into various nanosized pharmaceutical carriers,
such as liposomes (drugs are loaded into the hydrophobic membrane of the liposome),
micelles (drugs are loaded into the hydrophobic core of the micelle), and oil-in-water
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emulsions. However, many general problems are associated with these approaches. For
example, the nanocarriers exhibit relatively low loading efficacy of the drug into the
nanocarrier (between 0.5% and 25% by weight, and often below 10% by weight); the
protocols cannot be standardized, since each drug requires its own specific conditions for
solubilization; scaling up the technology is difficult; controlling surface properties or
surface composition of such nanosystems is difficult; and the nanocarriers have
insufficient storage stability and demonstrate instability in the body.

Summary of the Invention
The invention is based, at least in part, on the discovery of a universal platform for
making stable nanocolloids containing high concentration of water insoluble drugs. This
discovery was exploited to develop the invention, which, in one aspect, features a
nanoparticle comprising a compound; a first defined solid polymeric layer comprising a
first polymer, the first layer surrounding the compound; and a second defined solid
polymeric layer comprising a second polymer, the second layer surrounding the first
layer, the first polymer and the second polymer having opposite charges, and the
nanoparticle having a diameter of between about 100 nm and about 500 nm. In certain
embodiments, the nanoparticle has a diameter of between about 100 nm and about 450
nm, between about 100 nm and about 400 nm, between about 100 nm and about 300 nm,
between about 100 nm and about 250 nm, between about 100 nm and about 200 nm,
between about 100 nm and about 150 nm, or about 100 nm.
In some embodiments, the compound is present in the nanoparticle between about
5% by weight and about 95% by weight, between about 20% by weight and about 90%
by weight, between about 40% by weight and about 85% by weight, between about 60%
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by weight and about 85% by weight, between about 75% by weight to about 90% by
weight, and between about 80% by weight and about 90% by weight.
In other embodiments, the first polymeric layer and the second polymeric layer
have a combined thickness of between about 5 nm and about 30 nm, between about 5 nm
and about 25 nm, between about 5 nm and about 20 nm, between about 5 nm and about
15 nm, and between about 5 nm and about 10 nm.
In certain embodiments, the first polymer is positively charged and the second
polymer is negatively charged. In other embodiments, the first polymer is negatively
charged and the second polymer is positively charged.
In some embodiments, the compound is a therapeutic compound described herein.
In one embodiment, the compound is a cancer therapeutic described herein. In particular
embodiments, the compound is tamoxifen or paclitaxel.

In other embodiments, the

compound is a low soluble anticancer drugs, camptothecin, topotecan, irinotecan, KRN
5500 (KRN), meso-tetraphenylporphine, dexamethasone, a benzodiazepine, allopurinol,
acetohexamide,

benzthiazide,

chlorpromazine,

chlordiazepoxide,

haloperidol,

indomethacine, lorazepam, methoxsalen, methylprednisone, nifedipine, oxazepam,
oxyphenbutazone, prednisone, prednisolone, pyrimethamine, phenindione, sulfisoxazole,
sulfadiazine, temazepam, sulfamerazine, ellipticin, porphine derivatives for photodynamic therapy, and/or trioxsalen. In some embodiments, the nanoparticle contains
more than one type of compound.
In yet other embodiments, the first polymer is poly (dimethyldiallylamide
ammonium chloride) (PDDA), poly (allylamine hydrochloride) (PAH), or protamine
sulfate (PS).

In certain embodiments, the first polymer is poly (allylamine), poly
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(dimethyldiallyammonim chloride) polylysine, poly (ethylenimine), poly (allylamine),
dextran amine, polyarginine, chitosan, gelatine A, or protamine sulfate.

In some

embodiments, the second polymer is sodium poly (styrene sulphonate) (PSS) or human
serum albumin (HSA). In particular embodiments, the second polymer is polyglutamic
or alginic acids, poly(acrylic acid), poly(aspartic acid), poly(glutaric acid), dextran
sulfate, carboxymethyl cellulose, hyaluronic acid, sodium alginate, gelatine B,
chondroitin sulfate, and/or heparin.
In certain embodiments, the first polymer is a biocompatible and/or biodegradable
polymer.

In other embodiments, the second polymer is a biocompatible and/or

biodegradable polymer. In other embodiments, both the first and the second polymer are
biocompatible and/or biodegradable.
In yet other embodiments, the nanoparticle further comprises a third polymeric
layer surrounding the second polymeric layer.

In particular embodiments, the third

polymeric layer comprise a third polymer having an opposite charge from the second
polymer. In some embodiments, the third polymeric layer comprises PDDA. In certain
embodiments, the first polymer and the third polymer are the same.
In other embodiments, the compound is poorly soluble in water. In particular
embodiments, the compound has a solubility in aqueous medium of less than about 10
mg/ml, of less than about 5 mg/ml, of less than about 2.5 mg/ml, of less than about 1
mg/ml, or of less than about 0.5 mg/ml. In some embodiments, outermost polymeric
layer is modified with a targeting agent. In certain embodiments, the targeting agent is an
antibody. In particular embodiments, the antibody is an antibody against IL2 receptor a,
complement system protein C5, CD 11 a, CD20, TNF-alpha, T cell CD3 receptor, T cell
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VLA4 receptor, F protein of RSV, epidermal growth factor receptor, vascular endothelial
growth factor, glycoprotein Ilb/IIIa, CD52, or epidermal growth factor receptor. In other
embodiments, the antibody is a monoclonal 2C5 antibody.
In some embodiments, the nanoparticle does not contain a detergent, surfactant, or
oil. In other embodiments, the compound is released from the nanoparticle at a slower
rate. In another aspect, the invention features a nanoparticle comprising a compound; and
a polymeric coating comprising alternating polymeric layers of oppositely charged
polymers; the nanoparticle having a diameter of about 100 nm to about 500 nm. In
certain embodiments, the nanoparticle comprises two, three, four, five, or six polymeric
layers of oppositely charged polymers.
In certain embodiments, the nanoparticle has a diameter of between about 100 nm
and about 450 nm, between about 100 nm and about 400 nm, between about 100 nm and
about 300 nm, between about 100 nm and about 250 nm, between about 100 nm and
about 200 nm, between about 100 nm and about 150 nm, or about 100 nm.
In some embodiments, the polymers are polymers described herein. In particular
embodiments, the nanoparticle comprises a first polymeric layer

comprising

poly(dimethyldiallylamide ammonium chloride) (PDDA), poly(allylamine hydrochloride)
(PAH), or protamine sulfate (PS). In other embodiments, the nanoparticle comprises a
second polymeric layer comprising sodium poly (styrene sulphonate) (PSS) or human
serum albumin (HSA). In yet other embodiments, the nanoparticle comprises a third
polymeric layer comprising poly (dimethyldiallylamide ammonium chloride) (PDDA),
poly (allylamine hydrochloride) (PAH), or protamine sulfate (PS).

In still other

embodiments, the nanoparticle comprises a fourth polymeric layer comprising sodium
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poly (styrene sulphonate) (PSS) or human serum albumin (HSA). And in still other
embodiments, the nanoparticle comprises a fifth polymeric layer comprising poly
(dimethyldiallylamide ammonium chloride) (PDDA), poly (allylamine hydrochloride)
(PAH), or protamine sulfate (PS).

In yet another embodiment, the nanoparticle

comprises a sixth polymeric layer comprising sodium poly (styrene sulphonate) (PSS) or
human serum albumin (HSA).
In other embodiments, the compound is poorly soluble in water. In particular
embodiments, the compound has a solubility in aqueous medium of less than about 10
mg/ml, of less than about 5 mg/ml, of less than about 2.5 mg/ml, of less than about 1
mg/ml, or of less than about 0.5 mg/ml. In certain embodiments, the compound is a
therapeutic compound described herein.

In some embodiments, the compound is

tamoxifen or paclitaxel, and the compound is present between about 5% by weight and
about 95% by weight, between about 20% by weight and about 90% by weight, between
about 40% by weight and about 85% by weight, between about 60% by weight and about
85% by weight, between about 75% by weight to about 90% by weight, and between
about 80% by weight and about 90% by weight. In some embodiments, the nanoparticle
is a nanoparticle described herein.
In another aspect, the invention features a method of making a stable nanoparticle,
the method comprising subjecting a water-insoluble compound to ultrasonication; and
adding a first polymer to the compound in the presence of ultrasonication, the polymer
added at a concentration sufficient to form a stable first polymeric layer around the
compound.
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In some embodiments, after ultrasonication, the water-insoluble compound has a
negative charge in the absence of the polymer. In other embodiments, the polymer added
to the compound has a positive charge.
In particular embodiments, the ultrasonication is performed at about 20 °C to about
30 °C. In certain embodiments, the ultrasonication is performed at between about 10 °C
and about 40 °C, between about 15 °C and about 35 °C, or between about 10 °C and about
25 °C.
In certain embodiments, the nanoparticle has a diameter of between about 100 nm
and about 450 nm, between about 100 nm and about 400 nm, between about 100 nm and
about 300 nm, between about 100 nm and about 250 nm, between about 100 nm and
about 200 nm, between about 100 nm and about 150 nm, or about 100 nm.
In other embodiments, the compound is poorly soluble in water. In particular
embodiments, the compound has a solubility in aqueous medium of less than about 10
mg/ml, of less than about 5 mg/ml, of less than about 2.5 mg/ml, of less than about 1
mg/ml, or of less than about 0.5 mg/ml.
In certain embodiments, the compound is a therapeutic compound described
herein.

In some embodiments, the compound is tamoxifen or paclitaxel, and the

compound is present between about 5% by weight and about 95% by weight, between
about 20% by weight and about 90% by weight, between about 40% by weight and about
85% by weight, between about 60% by weight and about 85% by weight, between about
75% by weight to about 90% by weight, and between about 80% by weight and about
90% by weight. In some embodiments, the nanoparticle is a nanoparticle described
herein.
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In other embodiments, the first polymer is poly (dimethyldiallylamide ammonium
chloride) (PDDA), poly (allylamine hydrochloride) (PAH), or protamine sulfate (PS). In
particular embodiments, the method further comprising adding a second polymer to the
nanoparticle after the first polymeric layer is formed. In some embodiments, the second
polymer is sodium poly (styrene sulphonate) (PSS) or human serum albumin (HSA).
In yet another aspect, the invention features a method of treating a subject having a
tumor, the method comprising administering to the subject a nanoparticle in an amount
sufficient to reduce tumor size or number of tumor cells, wherein the nanoparticle
comprises a compound; a first defined solid polymeric layer comprising a first polymer,
the first layer surrounding the compound; and a second defined solid polymeric layer
comprising a second polymer, the second layer surrounding the first layer, the first
polymer and the second polymer having opposite charges, and the nanoparticle having a
diameter of about 100 run to about 500 nm.
In certain embodiments, the nanoparticle has a diameter of between about 100 nm
and about 450 nm, between about 100 nm and about 400 nm, between about 100 nm and
about 300 nm, between about 100 nm and about 250 nm, between about 100 nm and
about 200 nm, between about 100 nm and about 150 nm, or about 100 nm.
In certain embodiments, the compound is a therapeutic compound described
herein.

In some embodiments, the compound is tamoxifen or paclitaxel, and the

compound is present between about 5% by weight and about 95% by weight, between
about 20% by weight and about 90% by weight, between about 40% by weight and about
85% by weight, between about 60% by weight and about 85% by weight, between about
75% by weight to about 90% by weight, and between about 80% by weight and about
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90% by weight. In some embodiments, the nanoparticle is a nanoparticle described
herein.
In some embodiments, the subject is a vertebrate. In certain embodiments, the
subject is a mammal. In particular embodiments, the subject is a human.
Detailed Description of the Invention
Unless otherwise defined, all technical and scientific terms used herein have the
same meaning as commonly understood by one of ordinary skill in the art to which this
invention belongs.

Although methods and materials similar or equivalent to those

described herein can be used in the practice or testing of the present invention, suitable
methods and materials are described below.

All publications, patent applications,

patents, and other references mentioned herein, including GenBank database sequences,
are incorporated by reference in their entirety.

In case of conflict, the present

specification, including definitions, will control. In addition, the materials, methods, and
examples are illustrative only and not intended to be limiting. Other features and
advantages of the invention will be apparent from the following detailed description, and
from the claims.

Definitions
A "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse,
cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.
The term "biodegradable" refers to a substance that is decomposed (e.g.,
chemically or enzymatically) or broken down in component molecules by natural
biological processes (e.g., in vertebrate animals such as humans).
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The term "biocompatible" refers to a substance that has no unintended toxic or
injurious effects on biological functions in a target organism.
The term "targeting agent" refers to a ligand or molecule capable of specifically or
selectively (i.e., non-randomly) binding or hybridizing to, or otherwise interacting with, a
desired target molecule. Examples of targeting agents include, but are not limited to,
nucleic acid molecules (e.g., RNA and DNA, including ligand-binding RNA molecules
such as aptamers, antisense, or ribozymes), polypeptides (e.g., antigen binding proteins,
receptor ligands, signal peptides, and hydrophobic membrane spanning domains),
antibodies (and portions thereof), organic molecules (e.g., biotin, carbohydrates, and
glycoproteins), and inorganic molecules (e.g., vitamins). A nanoparticle described herein
can have affixed thereto one or more of a variety of such targeting agents.
The term "nanoparticle" refers to a particle having a diameter in the range of about
50 nm to about 1000 nm. Nanoparticles include particles capable of containing a
therapeutic or diagnostic agent that can be released within a subject.

The terms

"nanoparticle" and "nanocolloids" are used interchangeably herein.
The term, "about" means a numeric value having a range of ± 10% around the
cited value.
The term, "treat", "treating" or "treatment" refers to administering a therapy in an
amount, manner (e.g., schedule of administration), and/or mode (e.g., route of
administration), effective to improve a disorder (e.g., a disorder described herein) or a
symptom thereof, or to prevent or slow the progression of a disorder (e.g., a disorder
described herein) or a symptom thereof. This can be evidenced by, e.g., an improvement
in a parameter associated with a disorder or a symptom thereof, e.g., to a statistically
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significant degree or to a degree detectable to one skilled in the art. An effective amount,
manner, or mode can vary depending on the subject and may be tailored to the subject.
By preventing or slowing progression of a disorder or a symptom thereof, a treatment can
prevent or slow deterioration resulting from a disorder or a symptom thereof in an
affected or diagnosed subject.
A "solid" layer refers to a defined firm border between a compound within a
nanoparticle and the environment external to the compound. For example, nanoparticles
described herein can have one or more solid polymeric layers that reduce or restrict the
access of external molecules to the compound at the core of the nanoparticle.
The term "polymer", as used herein, refers to a molecule composed of repeated
subunits. Such molecules include, but are not limited to, polypeptides, polynucleotides,
polysaccharides or polyalkylene glycols. Polymers can also be biodegradable and/or
biocompatible.
The terms "polypeptide", "peptide", and "protein" are used interchangeably herein
and refer to a polymer of amino acid residues. The terms apply to naturally occurring
amino acid polymers as well as amino acid polymers in which one or more amino acid
residues are non-natural amino acids. Additionally, such polypeptides, peptides, and
proteins include amino acid chains of any length, including full length proteins, wherein
the amino acid residues are linked by covalent peptide bonds.
The term "stable" means that, for a period of at least six months after the
nanoparticles are made, a majority of the nanoparticles remain intact at RT. As used
herein, a compound that is "poorly soluble", when referring to a compound, means a
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compound that has a solubility in aqueous medium of less than about 10 mg/ml, such as
less than about 1 mg/ml.
The term "drug" refers to any substance used in the prevention, diagnosis,
alleviation, treatment, or cure of a disease or condition.
The term "zeta potential" means the electric potential across an ion layer, e.g., a
charged polymeric layer, around a charged colloidal nanoparticle.
The methods described in part, a layer-by-layer (LBL) coating technology to make
stable colloids of poorly soluble drugs. For this purpose, aqueous suspensions of poorly
soluble drugs with a particle size of the order of microns are subjected physical treatment,
such as ultrasonic treatment or ball milling (crushing), to decrease the size of individual
particles to the nanolevel (e.g., between about 25 nm and about 1000 nm, between about
100 nm and about 500 nm, or between about 100 nm and about 200 nm), which are then
stabilized in solution by the formation of a thin polymeric layer on their surface. This
polymeric layer prevents particle agglomeration after stopping the physical treatment,
which results in the formation of stable colloidal dispersions with high drug content in
each colloidal particle (e.g., more than about 50% by weight and up to about 90% by
weight).

The polymeric coating is formed based on a polyelectrolyte complexing

process, when drug nanosuspensions formed by, for example, ultrasonication, are
incubated in the presence of a water soluble, polymer (polycation or polyanion) to allow
for its deposition on their surface. The first polymeric layer can then be stabilized by the
addition of another, oppositely-charged polyelectrolyte, which forms a firm electrostatic
complex with the first layer. This results in the appearance of a very thin, but stable,
polymeric layer or shell around each nanoparticle of a compound. This shell can prevent
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particle agglomeration, and can be easily and reproducibly formed on the surface of any
compound particle. By varying the charge density on each polymer, or the number of
coating cycles, drug particles can be prepared with a different surface charge and
different thickness of the polymeric coat. This, in turn, provides a way to control drug
release from such particles.
LbL self-assembly of molecularly organized films was first developed with linear
polyions, nanoparticles, dyes and proteins for coating of large surfaces. The formation of
alternate outermost layers of the opposite charge at every adsorption cycle is an important
part of the procedure.

An alternate assembly of linear polyanions and polycations

typically provides 1-2 nm growth step for a single bilayer, and a number of bilayers,
which can be built up, can vary from one to few hundreds.
Compounds
A nanoparticle as described herein can contain many types of compounds, such as
therapeutic agents. Such therapeutic agents can be, but are not limited to, steroids,
analgesics,

local

anesthetics,

antibiotic

agents,

chemotherapeutic

agents,

immunosuppressive agents, anti-inflammatory agents, antiproliferative agents, antimitotic
agents, angiogenic agents, antipsychotic agents, central nervous system (CNS) agents;
anticoagulants, fibrinolytic agents, growth factors, antibodies, ocular drugs, and
metabolites, analogs, derivatives, fragments, and purified, isolated, recombinant and
chemically synthesized versions of these species, and combinations thereof.
Representative useful therapeutic agents include, but are not limited to, tamoxifen,
paclitaxel, low soluble anticancer drugs, camptothecin and its derivatives, e.g., topotecan
and

irinotecan,

KRN

5500

(KRN), meso-tetraphenylporphine,

dexamethasone,
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benzodiazepines,
chlordiazepoxide,

allopurinol,
haloperidol,

acetohexamide,

benzthiazide,

indomethacine,

chlorpromazine,

lorazepam,

methoxsalen,

methylprednisone, nifedipine, oxazepam, oxyphenbutazone, prednisone, prednisolone,
pyrimethamine, phenindione, sulfisoxazole, sulfadiazine, temazepam, sulfamerazine,
ellipticin, porphine derivatives for photo-dynamic therapy, and/or trioxsalen.

These

agents are commercially available from, e.g., Merck & Co., Barr Laboratories, Avalon
Pharma, and Sun Pharma, among others. Nanosized colloidal suspensions of poorly
soluble drugs can increase drug solubility and bioavailability.
Polymers
The nanoparticles described herein can be produced by encapsulating a compound
described herein within one or more layers of polymers, creating a defined polymeric
layer. In some instances, polycation polymers are used.

Such polycation polymers

include, without limitation, poly (allylamine), poly (dimethyldiallyammonim chloride)
polylysine, poly (ethylenimine), poly (allylamine), and natural polycations such as
dextran amine, polyarginine, chitosan, gelatine A, and/or protamine sulfate. In other
instances,

polyanion

polymers

are

used,

including,

without

limitation,

poly(styrenesulfonate), polyglutamic or alginic acids, poly(acrylic acid), poly(aspartic
acid), poly(glutaric acid), and natural polyelectrolytes with similar ionized groups such as
dextran sulfate, carboxymethyl cellulose, hyaluronic acid, sodium alginate, gelatine B,
chondroitin sulfate, and/or heparin. These polymers can be synthesized, isolated, or
commercially obtained.
In certain instances, biodegradable and/or biocompatible polymers are used.
These include, without limitation, substantially pure carbon lattices (e.g., graphite),
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dextran, polysaccharides, polypeptides, polynucleotides, acrylate gels, polyanhydride,
poly(lactide-co-glycolide), polytetraflouroethylene, polyhydroxyalkonates, cross-linked
alginates, gelatin, collagen, cross-linked collagen, collagen derivatives (such as
succinylated collagen or methylated collagen), cross-linked hyaluronic acid, chitosan,
chitosan derivatives (such as methylpyrrolidone-chitosan), cellulose and cellulose
derivatives (such as cellulose acetate or carboxymethyl cellulose), dextran derivatives
(such carboxymethyl dextran), starch and derivatives of starch (such as hydroxyethyl
starch),

other

glycosaminoglycans

and

their

derivatives,

other

polyanionic

polysaccharides or their derivatives, polylactic acid (PLA), polyglycolic acid (PGA), a
copolymer of a polylactic acid and a polyglycolic acid (PLGA), lactides, glycolides, and
other polyesters, polyglycolide homoploymers, polyoxanones

and polyoxalates,

copolymer of poly(bis(p-carboxyphenoxy)propane)anhydride (PCPP) and sebacic acid,
poly(l-glutamic acid), poly(d-glutamic acid), polyacrylic acid, poly(dl-glutamic acid),
poly(l-aspartic acid), poly(d-aspartic acid), poly(dl-aspartic acid), polyethylene glycol,
copolymers of the above listed polyamino acids with polyethylene glycol, polypeptides,
such as, collagen-like, silk-like, and silk-elastin-like proteins, polycaprolactone,
poly(alkylene succinates), poly(hydroxy butyrate) (PHB), poly(butylene diglycolate),
nylon-2/nylon-6-copolyamides, polydihydropyrans, polyphosphazenes, poly(ortho ester),
poly(cyano acrylates), polyvinylpyrrolidone, polyvinylalcohol, poly casein, keratin,
myosin, and fibrin, silicone rubbers, or polyurethanes, and the like. Other biodegradable
materials that can be used include naturally derived polymers, such as acacia, gelatin,
dextrans, albumins, alginates/starch, and the like; or synthetic polymers, whether
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hydrophilic or hydrophobic.

The materials can be synthesized, isolated, and are

commercially available.
Targeting Agents
In some instances, a nanoparticle described herein includes a targeting agent that is
attached, fixed, or conjugated to, the nanoparticle via the outermost layer of the
nanoparticle. In certain situations, the targeting agent specifically binds to a particular
biological target.

Nonlimiting examples of biological targets include tumor cells,

bacteria,

cell

viruses,

surface

proteins,

cell

surface

receptors,

cell

surface

polysaccharides, extracellular matrix proteins, intracellular proteins and intracellular
nucleic acids. The targeting agents can be, for example, various specific ligands, such as
antibodies, monoclonal antibodies and their fragments, folate, mannose, galactose and
other mono-, di-, and oligosaccharides, and RGD peptide.
The nanoparticles and methods described herein are not limited to any particular
targeting agent, and a variety of targeting agents can be used. Examples of such targeting
agents include, but are not limited to, nucleic acids (e.g., RNA and DNA), polypeptides
(e.g., receptor ligands, signal peptides, avidin, Protein A, and antigen binding proteins),
polysaccharides, biotin, hydrophobic groups, hydrophilic groups, drugs, and any organic
molecules that bind to receptors. In some instances, a nanoparticle described herein can
be conjugated to one, two, or more of a variety of targeting agents. For example, when
two or more targeting agents are used, the targeting agents can be similar or dissimilar.
Utilization of more than one targeting agent in a particular nanoparticle can allow the
targeting of multiple biological targets or can increase the affinity for a particular target.
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The targeting agents can be associated with the nanoparticles in a number of ways.
For example, the targeting agents can be associated (e.g., covalently or noncovalently
bound) to other subcomponents/elements of the nanoparticle with either short (e.g., direct
coupling), medium (e.g., using small-molecule bifunctional linkers such as SPDP (Pierce
Biotechnology, Inc., Rockford, IL)), or long (e.g., PEG bifunctional linkers (Nektar
Therapeutics, Inc., San Carlos, CA)) linkages. Alternatively, such agents can be directly
conjugated to the outermost polymeric layer.
In addition, polymers used to produce the nanoparticles described herein can also
incorporate reactive groups (e.g., amine groups such as polylysine, dextranemine,
profamine sulfate, and/or chitosan). The reactive group can allow for further attachment
of various specific ligands or reporter groups (e.g.,

125

I,

131

I, I, Br, various chelating

groups such as DTP A, which can be loaded with reporter heavy metals such as

m

In,

99m-Tc, GD, Mn, fluorescent groups such as FITC, rhodamine, Alexa, and quantum
dots), and/or other moieties (e.g., ligands, antibodies, and/or portions thereof). These
moieties can also be incorporated into the polymeric shell during its formation of a
nanoparticle described herein.
Antibodies as Targeting Agents
In some instances, the targeting agents are antigen binding proteins or antibodies
or binding portions thereof.

Antibodies can be generated to allow for the specific

targeting of antigens or immunogens (e.g., tumor, tissue, or pathogen specific antigens)
on various biological targets (e.g., pathogens, tumor cells, and normal tissue). Such
antibodies include, but are not limited to, polyclonal antibodies; monoclonal antibodies or
antigen binding fragments thereof; modified antibodies such as chimeric antibodies,
reshaped antibodies, humanized antibodies, or fragments thereof (e.g., Fv, Fab', Fab,
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F(ab')2); or biosynthetic antibodies, e.g., single chain antibodies, single domain antibodies
(DAB), Fvs, or single chain Fvs (scFv).
Methods of making and using polyclonal and monoclonal antibodies are well
known in the art [50]. Methods for making modified antibodies and antibody fragments
(e.g., chimeric antibodies, reshaped antibodies, humanized antibodies, or fragments
thereof, e.g., Fab', Fab, F(ab')2 fragments); or biosynthetic antibodies (e.g., single chain
antibodies, single domain antibodies (DABs), Fv, single chain Fv (scFv), and the like),
are known in the art and can be found [51].
In some instances, the antibodies recognize tumor specific epitopes (e.g., TAG-72
U.S. 5,892,020; 5,892,019; and 5,512,443) [52]; human carcinoma antigen (U.S.
5,693,763; 5,545,530; and 5,808,005); TP1 and TP3 antigens from osteocarcinoma cells
(U.S. 5,855,866); Thomsen-Friedenreich (TF) antigen from adenocarcinoma cells (U.S.
5,110,911); "KC-4 antigen" from human prostrate adenocarcinoma (U.S. 4,708,930 and
4,743,543); a human colorectal cancer antigen (U.S. 4,921,789); CA125 antigen from
cystadenocarcinoma (U.S. 4,921,790); DF3 antigen from human breast carcinoma (U.S.
4,963,484 and 5,053,489); a human breast tumor antigen (U.S. 4,939,240); p97 antigen of
human melanoma (U.S. 4,918,164); carcinoma or orosomucoid-related antigen (CORA)
(U.S. 4,914,021); a human pulmonary carcinoma antigen that reacts with human
squamous cell lung carcinoma but not with human small cell lung carcinoma (U.S.
4,892,935); T and Tn haptens in glycoproteins of human breast carcinoma [53], MSA
breast carcinoma glycoprotein [54]; MFGM breast carcinoma antigen [55]; DU-PAN-2
pancreatic carcinoma antigen [56]; CA125 ovarian carcinoma antigen [57]; and YH206
lung carcinoma antigen [58] .
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For example, to target breast cancer cells, the nanoparticles can be modified with
folic acid, EGF, FGF, and antibodies (or antibody fragments) to the tumor-associated
antigens MUC 1, cMet receptor and CD56 (NCAM).
Other antibodies that can be used recognize specific pathogens (e.g., Legionella
peomophilia, Mycobacterium tuberculosis, Clostridium tetani, Hemophilus influenzae,
Neisseria gonorrhoeae, Treponema pallidum, Bacillus anthracis, Vibrio cholerae,
Borrelia burgdorferi, Cornebacterium diphtheria, Staphylococcus aureus, human
papilloma virus, human immunodeficiency virus, rubella virus, and polio virus).
Antibodies or ligands that can be attached to the nanoparticles described herein
include, without limitation, antibodies to IL2 receptor a, complement system protein C5,
CD1 la, CD20, TNF-alpha, T cell CD3 receptor, T cell VLA4 receptor, F protein of RSV,
epidermal growth factor receptor, vascular endothelial growth factor, glycoprotein
Ilb/IIIa, CD52, and epidermal growth factor receptor.
Antibody attachment to nanoparticles can be performed through standard covalent
binding to free amine groups in the outermost polycation layer of polylysine or amine
dextran [59-61].
For example, during formation of a polycation /polyanion multilayer shell, at every
stage of the assembly, about 50% of pending ionized groups reacts with a previous layer,
and another about 50% is free at the outermost shell providing a surface charge indicated
by a given surface potential. Therefore, the number of amine or acidic reactive groups at
the outermost shell may correspond to half of the pending groups in the polymer, e.g.,
3,000 pending amine groups for poly (lysine) or poly (allylamine) in the outermost layer
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of a 100 ran diameter nanoshell.

Standard methods of protein covalent binding are

known, such as covalent binding through amine groups [62].
To activate the polymer coat of the particle, a polymer can be used for the last
layer of the particle which has free amino, carboxy, SH-, epoxy-, and/or other groups that
can react with ligand molecules directly or after preliminary activation with, e.g.,
carbodiimides, SPDP, SMCC, and/or other mono- and Afunctional reagents.
Signal Peptides as Targeting Agents
In some instances, the targeting agents include a signal peptide. These peptides
can be chemically synthesized or cloned, expressed and purified using known techniques.
Signal peptides can be used to target the nanoparticles described herein to a discreet
region within a cell. In some situations, specific amino acid sequences are responsible
for targeting the nanoparticles into cellular organelles and compartments. For example,
the signal peptides can direct a nanoparticle described herein into mitochondria. In other
examples, a nuclear localization signal is used.
Nucleic Acids as Targeting Agents
In other instances, the targeting agent is a nucleic acid (e.g., RNA or DNA). In
some examples, the nucleic acid targeting agents are designed to hybridize by base
pairing to a particular nucleic acid (e.g., chromosomal DNA, mRNA, or ribosomal RNA).
In other situations, the nucleic acids bind a ligand or biological target. For example, the
nucleic acid can bind reverse transcriptase, Rev or Tat proteins of HIV [63]; human nerve
growth factor [64]; or vascular endothelial growth factor [65]. Nucleic acids that bind
ligands can be identified by known methods, such as the SELEX procedure (see, e.g.,
U.S. 5,475,096; 5,270,163; and 5,475,096; and WO 97/38134; WO 98/33941; and WO
99/07724). The targeting agents can also be aptamers that bind to particular sequences.
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Other Targeting Agents
The targeting agents can recognize a variety of epitopes on preselected biological
targets (e.g., pathogens, tumor cells, or normal cells). For example, in some instances,
the targeting agent can be sialic acid to target HIV [66], influenza [67], Chlamydia [68],
Neisseria meningitidis, Streptococcus suis, Salmonella, mumps, newcastle, reovirus,
Sendai virus, and myxovirus; and 9-OAC sialic acid to target coronavirus,
encephalomyelitis virus, and rotavirus; non-sialic acid glycoproteins to target
cytomegalovirus [69] and measles virus [70]; CD4 [71], vasoactive intestinal peptide
[72], and peptide T [73] to target HIV; epidermal growth factor to target vaccinia [74];
acetylcholine receptor to target rabies [75]; Cd3 complement receptor to target EpsteinBarr virus [76]; .beta.-adrenergic receptor to target reovirus [77]; ICAM-1 [78], N-CAM,
and myelin-associated glycoprotein MAb [79] to target rhinovirus; polio virus receptor to
target polio virus [80]; fibroblast growth factor receptor to target herpes virus [81];
oligomannose to target Escherichia coli; and ganglioside GMI to target Neisseria
meningitides.
In other instances, the targeting agent targets nanoparticles according to the
disclosure to factors expressed by oncogenes. These can include, but are not limited to,
tyrosine kinases (membrane-associated and cytoplasmic forms), such as members of the
Src family; serine/threonine kinases, such as Mos; growth factor and receptors, such as
platelet derived growth factor (PDDG), SMALL GTPases (G proteins), including the ras
family, cyclin-dependent protein kinases (cdk), members of the myc family members,
including c-myc, N-myc, and L-myc, and bcl-2 family members.
In addition, vitamins (both fat soluble and non-fat soluble vitamins) can be used as
targeting agents to target biological targets (e.g., cells) that have receptors for, or
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otherwise take up, vitamins. For example, fat soluble vitamins (such as vitamin D and its
analogs, vitamin E, Vitamin A), and water soluble vitamins (such as Vitamin C) can be
used as targeting agents.
Therapeutic Administration
The nanoparticles described herein can be used to treat (e.g., mediate the
translocation of drugs into) diseased cells and tissues. In this regard, various diseases are
amenable to treatment using the nanoparticles and methods described herein.

An

exemplary, nonlimiting list of diseases that can be treated with the subject nanoparticles
includes breast cancer; prostate cancer; lung cancer; lymphomas; skin cancer; pancreatic
cancer; colon cancer; melanoma; ovarian cancer; brain cancer; head and neck cancer;
liver cancer; bladder cancer; non-small lung cancer; cervical carcinoma; leukemia;
neuroblastoma and glioblastoma; T and B cell mediated autoimmune diseases;
inflammatory diseases; infections; hyperproliferative diseases; AIDS; degenerative
conditions, vascular diseases, and the like. In some cases, the treated cancer cells are
metastatic. The route and/or mode of administration of a nanoparticle described herein
can vary depending upon the desired results. Dosage regimens can be adjusted to provide
the desired response, e.g., a therapeutic response.
Methods of administration include, but are not limited to, intradermal,
intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral,
sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topical,
particularly to the ears, nose, eyes, or skin. The mode of administration is left to the
discretion of the practitioner.

78

In some instances, a nanoparticle described herein is administered locally. This is
achieved, for example, by local infusion during surgery, topical application (e.g., in a
cream or lotion), by injection, by means of a catheter, by means of a suppository or
enema, or by means of an implant, said implant being of a porous, non-porous, or
gelatinous material, including membranes, such as sialastic membranes, or fibers. In
some situations, a nanoparticle described herein is introduced into the central nervous
system, circulatory system or gastrointestinal tract by any suitable route, including
intraventricular, intrathecal injection, paraspinal injection, epidural injection, enema, and
by injection adjacent to the peripheral nerve. Intraventricular injection can be facilitated
by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya
reservoir.
This disclosure also features a device for administering a nanoparticle described
herein. The device can include, e.g., one or more housings for storing pharmaceutical
compositions, and can be configured to deliver unit doses of a nanoparticle described
herein.
Pulmonary administration can also be employed, e.g., by use of an inhaler or
nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon
or synthetic pulmonary surfactant.
In some instances, a nanoparticle described herein can be delivered in a vesicle, in
particular, a liposome [82, 83].
In yet other situations, a nanoparticle described herein can be delivered in a
controlled-release system or sustained-release system [84].

Other controlled or

79
sustained-release systems discussed in the review by Langer, Science 249:1527-1533
(1990) can be used. In one case, a pump can be used [82, 85-87].
In yet other situations, a controlled- or sustained-release system can be placed in
proximity of a target of nanoparticle described herein, reducing the dose to a fraction of
the systemic dose.
A nanoparticle described herein is formulated as a pharmaceutical composition
that includes a suitable amount of a physiologically acceptable excipient [88]. Such
physiologically acceptable excipients can be, e.g., liquids, such as water and oils,
including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil,
soybean oil, mineral oil, sesame oil and the like.

The physiologically acceptable

excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica,
urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring
agents can be used. In one situation, the physiologically acceptable excipients are sterile
when administered to an animal. The physiologically acceptable excipient should be
stable under the conditions of manufacture and storage and should be preserved against
the contaminating action of microorganisms. Water is a particularly useful excipient
when a nanoparticle described herein is administered intravenously. Saline solutions and
aqueous dextrose and glycerol solutions can also be employed as liquid excipients,
particularly for injectable solutions. Suitable physiologically acceptable excipients also
include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel,
sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol,
propylene, glycol, water, ethanol and the like. Other examples of suitable physiologically
acceptable excipients are described in reference [88]. The pharmaceutical compositions,
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if desired, can also contain minor amounts of wetting or emulsifying agents, or pH
buffering agents.
Liquid carriers can be used in preparing solutions, suspensions, emulsions, syrups,
and elixirs. A nanoparticle described herein can be suspended in a pharmaceutically
acceptable liquid carrier such as water, an organic solvent, a mixture of both, or
pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable
pharmaceutical additives including solubilizers, emulsifiers, buffers, preservatives,
sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity
regulators, stabilizers, or osmo-regulators. Suitable examples of liquid carriers for oral
and parenteral administration include water (particular containing additives described
herein, e.g., cellulose derivatives, including sodium carboxymethyl cellulose solution),
alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their
derivatives, and oils (e.g., fractionated coconut oil and arachis oil).

For parenteral

administration the carrier can also be an oily ester such as ethyl oleate and isopropyl
myristate. The liquid carriers can be in sterile liquid form for administration. The liquid
carrier for pressurized compositions can be halogenated hydrocarbon or other
pharmaceutically acceptable propellant.
In other instances, a nanoparticle described herein is formulated for intravenous
administration.

Compositions for intravenous administration can comprise a sterile

isotonic aqueous buffer.

The compositions can also include a solubilizing agent.

Compositions for intravenous administration can optionally include a local anesthetic
such as lignocaine to lessen pain at the site of the injection. The ingredients can be
supplied either separately or mixed together in unit dosage form, for example, as a dry
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lyophilized powder or water-free concentrate in a hermetically sealed container such as
an ampule or sachette indicating the quantity of active agent. Where a nanoparticle
described herein is administered by infusion, it can be dispensed, for example, with an
infusion bottle containing sterile pharmaceutical grade water or saline.

Where a

nanoparticle described herein is administered by injection, an ampule of sterile water for
injection or saline can be provided so that the ingredients can be mixed prior to
administration.
In other circumstances, a nanoparticle described herein can be administered across
the surface of the body and the inner linings of the bodily passages, including epithelial
and mucosal tissues.

Such administrations can be carried out using a nanoparticle

described herein in lotions, creams, foams, patches, suspensions, solutions, and
suppositories (e.g., rectal or vaginal). In some instances, a transdermal patch can be used
that contains a nanoparticle described herein and a carrier that is inert to the nanoparticle
described herein, is non-toxic to the skin, and that allows delivery of the agent for
systemic absorption into the blood stream via the skin. The carrier can take any number
of forms such as creams or ointments, pastes, gels, or occlusive devices. The creams or
ointments can be viscous liquid or semisolid emulsions of either the oil in water or water
in oil type.

Pastes of absorptive powders dispersed in petroleum or hydrophilic

petroleum containing a nanoparticle described herein can also be used. A variety of
occlusive devices can be used to release a nanoparticle described herein into the blood
stream, such as a semi-permeable membrane covering a reservoir containing the
nanoparticle described herein with or without a carrier, or a matrix containing the
nanoparticle described herein.
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A nanoparticle described herein can be administered rectally or vaginally in the
form of a conventional suppository.

Suppository formulations can be made using

methods known to those in the art from traditional materials, including cocoa butter, with
or without the addition of waxes to alter the suppository's melting point, and glycerin.
Water-soluble suppository bases, such as polyethylene glycols of various molecular
weights, can also be used.
The amount of a nanoparticle described herein that is effective for treating disorder
or disease is determined using standard clinical techniques known to those with skill in
the art. In addition, in vitro or in vivo assays can optionally be employed to help identify
optimal dosage ranges. The precise dose to be employed can also depend on the route of
administration, the condition, the seriousness of the condition being treated, as well as
various physical factors related to the individual being treated, and can be decided
according to the judgment of a health-care practitioner. For example, the dose of a
nanoparticle described herein can each range from about 0.001 mg/kg to about 250 mg/kg
of body weight per day, from about 1 mg/kg to about 250 mg/kg body weight per day,
from about 1 mg/kg to about 50 mg/kg body weight per day, or from about 1 mg/kg to
about 20 mg/kg of body weight per day. Equivalent dosages can be administered over
various time periods including, but not limited to, about every 2 hr, about every 6 hr,
about every 8 hr, about every 12 hr, about every 24 hr, about every 36 hr, about every 48
hr, about every 72 hr, about every week, about every two weeks, about every three
weeks, about every month, and about every two months. The number and frequency of
dosages corresponding to a completed course of therapy can be determined according to
the judgment of a health-care practitioner.
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In some instances, a pharmaceutical composition described herein is in unit dosage
form, e.g., as a tablet, capsule, powder, solution, suspension, emulsion, granule, or
suppository. In such form, the pharmaceutical composition can be sub-divided into unit
doses containing appropriate quantities of a nanoparticle described herein. The unit
dosage form can be a packaged pharmaceutical composition, for example, packeted
powders, vials, ampoules, pre-filled syringes or sachets containing liquids. The unit
dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate
number of any such compositions in package form. Such unit dosage form can contain
from about 1 mg/kg to about 250 mg/kg, and can be given in a single dose or in two or
more divided doses.
Nanoparticle Drug Kits
A nanoparticle described herein can be provided in a kit. In some instances, the kit
includes (a) a container that contains a nanoparticle and, optionally (b) informational
material. The informational material can be descriptive, instructional, marketing or other
material that relates to the methods described herein and/or the use of the nanoparticles,
e.g., for therapeutic benefit.
The informational material of the kits is not limited in its form. In some instances,
the informational material can include information about production of the nanoparticle,
molecular weight of the nanoparticle, concentration, date of expiration, batch or
production site information, and so forth. In other situations, the informational material
relates to methods of administering the nanoparticles, e.g., in a suitable amount, manner,
or mode of administration (e.g., a dose, dosage form, or mode of administration described
herein). The method can be a method of treating a subject having a disorder.
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In some cases, the informational material, e.g., instructions, is provided in printed
matter, e.g., a printed text, drawing, and/or photograph, e.g., a label or printed sheet. The
informational material can also be provided in other formats, such as Braille, computer
readable material, video recording, or audio recording.

In other instances, the

informational material of the kit is contact information, e.g., a physical address, email
address, website, or telephone number, where a user of the kit can obtain substantive
information about the nanoparticles therein and/or their use in the methods described
herein. Of course, the informational material can also be provided in any combination of
formats.
In addition to the nanoparticles, the kit can include other ingredients, such as a
solvent or buffer, a stabilizer, or a preservative. The kit can also include other agents,
e.g., a second or third agent, e.g., other therapeutic agents. The components can be
provided in any form, e.g., liquid, dried or lyophilized form. The components can be
substantially pure (although they can be combined together or delivered separate from
one another) and/or sterile. When the components are provided in a liquid solution, the
liquid solution can be an aqueous solution, such as a sterile aqueous solution. When the
components are provided as a dried form, reconstitution generally is by the addition of a
suitable solvent. The solvent, e.g., sterile water or buffer, can optionally be provided in
the kit.
The kit can include one or more containers for the nanoparticles or other agents.
In some cases, the kit contains separate containers, dividers or compartments for the
nanoparticles and informational material.

For example, the nanoparticles can be

contained in a bottle, vial, or syringe, and the informational material can be contained in a
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plastic sleeve or packet. In other situations, the separate elements of the kit are contained
within a single, undivided container. For example, the nanoparticles can be contained in
a bottle, vial or syringe that has attached thereto the informational material in the form of
a label.

In some cases, the kit can include a plurality (e.g., a pack) of individual

containers, each containing one or more unit dosage forms (e.g., a dosage form described
herein) of the nanoparticles. The containers can include a unit dosage, e.g., a unit that
includes the nanoparticles. For example, the kit can include a plurality of syringes,
ampules, foil packets, blister packs, or medical devices, e.g., each containing a unit dose.
The containers of the kits can be air tight, waterproof (e.g., impermeable to changes in
moisture or evaporation), and/or light-tight.
The kit can optionally include a device suitable for administration of the
nanoparticles, e.g., a syringe or other suitable delivery device.

The device can be

provided pre-loaded with nanoparticles, e.g., in a unit dose, or can be empty, but suitable
for loading.
The invention is further illustrated by the following examples. The examples are
provided for illustrative purposes only. They are not to be construed as limiting the scope
or content of the invention in any way.
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Examples
Example 1; Preparation of Stable
Nanocolloids of Poorly Soluble
Drugs
Stable colloids of poorly soluble drugs were prepared in order to increase their
solubilization and bioavailability. To do this, high power sonication of poorly soluble
drug aqueous dispersions is used with simultaneous LbL-nanocoating.

Such coating

reverses and enhances a particle surface charge which prevents re-aggregation of the drug
and allows for getting smaller and smaller drug colloids (proportionally to the sonication
time).
A simultaneous application of powerful sonication and adsorption of opposite
charged polyelectrolytes caused a systematic decrease of insoluble drug particle size to
nano-scale in the following process (depicted schematically in Figure 6.1). Sonication
energy initially cleaves and cracks the bulk drug, and polyelectrolytes immediately fix
this sub-dividing, preventing re-aggregation of the pieces.

Longer sonication times

allowed for smaller and smaller particles (to about 100 nm diameter) which are stable in
water due to an adsorbed monolayer of polyelectrolytes.

Further build-up of an

organized multilayer shell through LbL architecture (alternate adsorption of polycations
and polyanions) caused the formation of thicker shells of about 5 nm to about 30 nm,
which controlled the drug release rate.
Methods
Materials and Instruments
The poorly soluble and potent anti-cancer drugs tamoxifen (TMF) and paclitaxel
(PCT) were used in these experiments (solubility below 1 |xg/mL). All polyelectrolytes
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used for the LbL assembly were used at a concentration of 2 mg/mL. Poly (allylamine
hydrochloride) (PAH), FITC-labeled PAH, and poly (dimethyldiallylamide ammonium
chloride) (PDDA) were used as positively charged polyelectrolytes.

Sodium poly

(styrene sulphonate) (PSS) was used as a negatively charged polyelectrolyte. Deionized
water and PBS at pH 7.4 were used as solvents. Drug crystal disintegrations were
performed using an Ultra Sonicator 3000 (Misonix Inc, Farmingdale, NY) at 3-18 W for
10-30 minute. To prevent sample overheating during the sonication and to keep the
temperature in the range of 20-30°C, liquid nitrogen was used to cool the sample tubes.
The thickness of the polyelectrolyte multilayer was measured using a Quartz Crystal
Microbalance (9 MHz QCM, USI-System, Japan). Surface potential (zeta potential) and
particle size measurements were performed using ZetaPlus Microelectrophoresis
(Brookhaven Instruments). A Field Emission Scanning Electron Microscope (Hitachi)
was used for particle imaging. A Laser Scanning Confocal Microscope (Leica TCS SP2
from Leica Microsystems Inc.) was also used to control shell formation and to follow
colloid stability.
LbL Assembly and Properties of
Nanoparticles
Initially, all drug samples were disintegrated using ultrasonication with cooling at
18 W for up to 30 minutes in 1 mL volume before any polyelectrolyte was added. The
size of the drug particles formed was periodically measured. Prior to the addition of the
first layer of polyelectrolyte, the zeta potential reading was also taken. Polycations were
used to form the first surface layer, since drug nanoparticles of both drugs were found to
bear an intrinsic negative charge. Drug samples were then centrifuged at 14,000 rpm for
7 minute, washed, and re-suspended in either water or PBS to remove excess
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polyelectrolyte.

Zeta potential readings were then taken.

The coating process was

repeated using the polyanion polymer but without ultrasonication.

Zeta potential

measurements were taken after each layer was added.
Images of colloidal particles formed were taken both immediately and at 48 hrs
following LbL assembly to analyze the stability of the colloids formed. Dry samples
were prepared for SEM imaging using 5 uL -10 uL of the colloidal suspension obtained.
Sample droplets on bare silicon wafers were dried by heating them at 50°C for 1 hr or by
storing them overnight at RT. Drug colloids were kept in a low volume of saturated
solution to prevent drug release.
Drug Release from Colloidal
Particles at Sink Conditions
To determine the release rate of different drugs from the colloidal particles
prepared using LbL assembly, samples prepared using differing numbers of coating
cycles were placed in 1 mL horizontal diffusion chambers made of cellulose acetate
membrane. The samples were then stirred in a large volume of PBS, pH 7.2, to mimic
the sink conditions expected in vivo. The concentrations of the released drugs were
measured by HPLC.
Attachment of Ligand Moieties to
the LbL Nanocolloids of Poorly
Soluble Drugs
To prepare nanocolloids with a "reactive" surface suitable for covalent attachment
of various ligands, PAH containing free amino groups was used to form the outer layer
on the drug particles. Paclitaxel was used as the drug in this series of experiments. The
monoclonal nucleosome-specific 2C5 antibody (mAb 2C5) was conjugated to LbL
paclitaxel nanoparticles. This antibody recognizes a broad variety of cancer cells via
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cancer cell surface-bound nucleosomes [41, 42]. The antibody was conjugated in two
steps (Figure 6.2). In the first step, the carboxylate groups on mAb 2C5 were activated
using l-ethyl-3-carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide
(sulfo-NHS), rendering the antibody amine-reactive. In the second step, the activated
antibody was added to LbL paclitaxel nanoparticles coated with polyamino-containing
PAH polymer. All reactions were carried out in HBS, pH 7.4, at 4°C with continuous
stirring in the presence of argon gas. The modified particles were centrifuged at 12 rpm
for 10 minute and re-suspended twice using PBS to remove unconjugated antibody.
The amount of paclitaxel in the nanoparticle preparations was measured by
reversed phase HPLC. A D-7000 HPLC system equipped with a diode array (Hitachi,
Japan) and Spherisorb ODS2 column, 4.6 mm x 250 mm (Waters, Milford, MA, USA)
was used. The particles were dissolved with the mobile phase prior to loading into the
HPLC column. The column was eluted with acetonitrile/water (65:35%, v/v) at 1.0
mL/min. A Paclitaxel peak was detected at 227 nm. Injection volume was 50 uL. All
samples were analyzed in triplicate.
Antibody Activity Preservation on
the Surface of LbL Drug
Nanoparticles
To verify the preservation of mAb 2C5 specific activity after the conjugation with
LbL-paclitaxel nanoparticles, a standard ELISA was performed. Briefly, ELISA plates
pretreated with 40 (Ag/ml polylysine solution in TBS, pH 7.4, were coated with 50 uL of
40 jj,g/mL nucleosomes (the water-soluble fraction of calf thymus nucleohistone,
Worthington Biochemical, Lakewood, NJ) and incubated for 1 hr at RT. The plates were
then rinsed with 0.2% casein, 0.05% Tween 20 in TBS (casein/TBS), pH 7.4. To these
plates, serial dilutions of mAb 2C5-containing samples were added and incubated for 1 hr
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at RT. The plates were extensively washed with casein/TBS and coated with horseradish
peroxidase goat anti-mouse IgG conjugate (ICN Biomedical, Aurora, OH), diluted
according to the manufacturer's recommendation. After 1 hr incubation at RT, the plates
were washed with casein/TBS. Bound peroxidase was quantified by the degradation of
its substrate, diaminobenzidine, supplied as a ready-for-use solution, Enhanced K-Blue
TMB substrate (Neogen, Lexington, KY). The intensity of the color developed was
analyzed using a Labsystems Multiscan MCC/340 ELISA reader at 492 nm (Labsystems
and Life Sciences International, UK).
Cytotoxicity of Targeted Paclitaxel
LbL Nanoparticles
The cytotoxicity of various concentrations of LbL-paclitaxel nanoparticles against
MCF-7 and BT-20 cells was studied using an MTT test. A ready-for-use CellTiter 96®
Aqueous One solution of MTT (Promega, Madison, WI) was used according to the
manufacturer's protocol. Formulations with paclitaxel concentration of up to 200 ng/mL
dispersed in Hank's buffer were added to cells grown in 96-well plates to about 40%
confluence. After 48 hr or 72 hr of incubation at 37°C, 5% CO2, plates were washed
three times with Hank's buffer.

Next, 100 ul of media and 20 ul of CellTiter 96®

Aqueous One solution were added to the plates, and the plates were incubated for 1 hr at
37°C, 5% C0 2 .

The cell survival rate was then estimated by measuring the color

intensity of the MTT degradation product at 492 nm using an ELISA plate reader.
Untreated cells were considered as 100% growth.
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Results
LbL-Stabilized Drug
Nanoparticles and Surface Zeta
Potential
To find optimal sonication conditions, initial experiments were performed with
tamoxifen crystals at a concentration of 2 mg/ml in the suspension. As shown in Figure
6.3, particle size could be controlled by the duration of sonication, and decreased with
increased sonication time. After 30 minutes of sonication at 18 W, particles of about 100
nm were obtained (polycationic PDDA was added prior to the size measurement to
prevent particle re-aggregation). When similar sonication conditions were applied to
paclitaxel crystals, particle sizes of about 100 nm were also obtained. Increasing the
sonication time further did not result in a significant decrease in drug particle size.
As depicted in Figure 6.4, no surface charge for tamoxifen was observed after
normal bath sonication, but a strong negative charge was obtained just after 2.5 sec pulse
power sonication.

Sequential addition of layers of PAH and PSS resulted in

nanoparticles having positive and negative charges, respectively.
Zeta potential was measured during the process of sequential PDDA/PSS
adsorption onto tamoxifen cores. After the addition of PDDA, the initially negatively
charged nanoparticles were recharged to a positive potential of about +45 mV. The
addition of PDDA formed a stable colloidal solution when sonication was terminated.
The polyanion PSS was then added to the PDDA-coated tamoxifen nanoparticles, in the
presence of sonication, to perform LbL assembly. PSS polyanion adsorption added one
more monolayer to the shell, and again reversed the surface potential to a negative value
(-17 mV). Next, the PDDA polycation was added again, which resulted in tamoxifen
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particles that were positively charged (around +80 mV). Addition of a fourth polymer
layer of the polyanion PSS resulted in tamoxifen particles that were again negative.
Alternating layers of PDDA and PSS were added to the tamoxifen particles until
tamoxifen nanoparticles were formed that were coated with an organized multilayer shell
with the composition (PDDA/PSS)3.
Sonicated paclitaxel particles were also initially negatively charged (Figure 6.5).
When paclitaxel was coated with either PAH or PDDA, the surface charge was reversed
after sonication (Figure 6.5).

When the polyanion PSS was subsequently added to

paclitaxel/PAH nanoparticles, the resulting nanoparticles had a negative zeta potential.
Further assembly using alternating additions of PAH and PSS under sonication resulted
in nanoparticles having corresponding changes in zeta potential values, until paclitaxel
nanoparticles were formed having a composition of (PAH/PSS)2 .
In separate experiments using quartz Crystal Microbalance (QCM) monitoring of
the PDDA/PSS or PAH/PSS assembly on quartz resonator, a single polycation/polyanion
bilayer was determined to have a thickness of 1.5 nm in the dry state. As polyelectrolyte
multilayer thickness doubles in water [22, 28], the thickness of the (PDDA/PSS)3 shells
was estimated to be around 4.5 nm in the dry state and around 9 nm in aqueous solution.
(PAH/PS S)2 shell thickness was estimated to be around 3 nm in the dry state and 6 nm in
aqueous solution.
Nanoparticle Imaging and Some
Properties
Scanning electron microscopy (SEM) and confocal fluorescence microscopy were
used to confirm the sizes of the nanoparticles formed by the LbL technology described
herein. After tamoxifen was sonicated for 20 minutes in the presence of 2 mg/ml PAH,
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nanoparticles were obtained that were mainly spherical in shape and had a diameter of
120 ± 30 nm (Figures 6.6 and 6.7). The nanocolloids were stable in water, since SEM
images taken after 48 hrs still showed individual non-agglomerated nanosized particles.
Adding a first layer of polyanion PSS did not result in tamoxifen size decrease even after
20 minute of sonication.
For paclitaxel, nanoparticles having a (PAH-PSS)2 shell composition were
produced having particle sizes of about 91 nm and about 300 nm (Figures 6.9C and 6.10).
However, aggregation of some paclitaxel nanoparticles to about 1.5 um diameter particles
was observed.

Reducing the initial paclitaxel concentration to 1 mg/ml resulted in

nanoparticles having an elongated rod-like shape with dimensions of about 50 nm x about
120 nm, which did not aggregate.
The SEM images were obtained after drying the samples, and during the drying
process the nanoparticles become partially aggregated.

To demonstrate that this

aggregation was the result of SEM sample preparation and that the nanoparticles did not
aggregate in aqueous suspension, images of the samples were obtained using confocal
fluorescence microscopy.
Tamoxifen nanoparticles were prepared by coating tamoxifen with a layer of
FITC-labeled PAH. Fluorescence imaging of these LbL-coated tamoxifen particles in
suspension did not reveal any aggregation (Figure 6.11). Paclitaxel nanoparticles coated
with FITC-labeled PAH also did not aggregate.

Further assembly of PAH-coated

tamoxifen nanoparticles, through alternate sequential adsorption of PSS and PAH to build
a multilayer was performed, in which the last PAH layer was labeled with FITC.
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Figure 6.11 depicts a confocal image of a tamoxifen nanoparticle demonstrating effective
LbL encapsulation within a three layer shell.
In other experiments, SEM and confocal images were obtained 2-7 days after
sample formation, demonstrating the stability of aqueous drug nanocolloids.
Given that the thickness of a single polymeric layer was about 1.5 nm in dry state,
the amount of drug in the stable nanocolloidal particles was calculated to be from about
85% by weight (for tamoxifen particles with the triple PDDA/PSS bilayer coating) to
about 90% by weight (for paclitaxel particles with the double PAH/PSS layer coating).
Further, colloidal suspensions of both drugs were completely stable during the two weeks
of observation.
Drug Release From LbL
Nanoparticles
LbL technology can be used to control the drug release rate from polymerstabilized colloidal nanoparticles by changing the thickness or composition of the
nanoparticles. Accordingly, the release of tamoxifen from LbL nanocolloidal particles
containing 2 mg/mL tamoxifen and having a single PDDA coating or a coating
composition of (PDDA/PSS)3 was measured in standard sink conditions (PBS buffer at
pH 7.4). Curves were produced from the experimental data using Peppas' model of
exponential approximation [43]. As depicted in Figures 3.9 and 4.4, slower release rates
were observed as the number of polyelectrolyte layers in the shell increased. At sink
conditions (PBS buffer at pH 7.4), non-coated tamoxifen crystals (both without and with
sonication) were solubilized within about 2 hrs.

PDDA- and (PDDA/PSS)3-coated

nanoparticles were estimated to solubilize at around 10 hrs. Similar results were obtained
for paclitaxel.

Slower release rates were obtained using LbL coatings containing
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different polycations and polyanions and varying the number of shells. Similar results
were seen for paclitaxel nanoparticles.
Surface Modification of LbLcoated Drug Nanoparticles and
Cytotoxicity Analysis
To demonstrate the ability to derivatize the LbL-coated drug nanoparticles,
paclitaxel-containing nanoparticles were produced having one layer of PAH, as described
above. The tumor-specific mAb 2C5 was then attached to the PAH-coated paclitaxel
nanoparticles via free amino groups on the surface layer of PAH. It was depicted that
2C5-modified LbL-coated paclitaxel nanoparticles specifically recognized the target
antigen (i.e., nucleosomes).
The cytotoxicity of the mAb 2C5-modified paclitaxel-containing nanoparticles
was determined using MCF-7 cells and BT-20 cells, as described above. Paclitaxel
nanoparticles having a single layer of PAH, but without the 2C5 modification, were used
as control. After incubating MCF-7 cells for 48 hrs or 72 hrs in the presence of 100
ng/mL unmodified paclitaxel nanoparticles, about 95% of the cells were alive. However,
when MCF-7 cells were incubated in the presence of 100 ng/ml 2C5-modified paclitaxelcontaining nanoparticles, around 30% of the cells were killed. Similar results were seen
when BT-20 cells were incubated in the presence of 30 ng/ml of paclitaxel nanoparticles.
Example 2;Preparation of Stable
Nanoparticles of mesoTetraphenylporphyrin and
Camptothecin
LbL nanoparticles of meso-tetraphenylporphyrin and camptothecin were prepared
as described in Example 1.

As depicted in Figure 6.12, /weso-tetraphenylporphyrin

nanoparticles were produced using a coating of FITC-labeled PAH, which reversed the
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surface charge from negative to positive.

SEM analysis demonstrated particle sizes

ranging from about 83 nm to about 194 nm (Figure 6.12).
LbL nanoparticles of camptothecin were also prepared. Optimization of the first
polycation coating was performed. Three polycations (PAH, PEI and PDDA) and one
polyanion (PSS) were used. In the presence of PSS, which has the same charge as the
drug core, no particle size decrease was observed (Figure 6.13). All the polycations were
able to reduce the particle size, and the smallest particles were obtained with polylysine
treatment. SEM images of camptothecin after 30 minutes of sonication with cationic
poly L-lysine detected particles of about 390 nm, whereas sonication with PSS resulted in
larger particles.
Some representative results are summarized below in Table 1. The release time
for tamoxifen was about 6 hrs.
Table 1. Physical characteristics and dimensions of drug nanoparticles.
Drugs

Particle Size

Coating Thickness

Colloidal Stability

Tamoxifen

125±30nm

5 nm

<= 7 Days

Paclitaxel

110±30nm

5 nm

<= 7 Days

mesoTetraphenylporphine

140±50nm

5 nm

<= 7 Days

Camptothecin

390±50nm

5 nm

<= 7 Days

Example 3: Preparation of Stable
Nanoparticles of Paclitaxel Using
Biocompatible Coatings
LbL drug nanoparticles of paclitaxel were prepared as described in Example 1, but
biocompatible materials were used in the coatings. Paclitaxel-containing nanoparticles
were prepared with a first layer of protamine sulfate (PS) followed by subsequent
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coatings of human serum albumin (HSA). Smaller nanoparticles were obtained with 30
minute sonication + LbL coating with protamine sulfate.
Figure 4.3 depicts zeta potential readings of paclitaxel LbL by biocompatible PS
and BSA. As demonstrated, the charge alternates between positive and negative values
with each subsequent addition of PS and HSA, respectively.
To determine the release of paclitaxel from these nanoparticles, the release rates
through 200 nm membranes over 2 hrs were measured, as described in Example 1. As
shown in Figure 4.4, at 2 hrs, 12.06 % paclitaxel was released from naked paclitaxel with
sonication, 9.7% of paclitaxel was released from particles with 1 layer of PDDA, 7.41%
paclitaxel was released from particles having two (PS-HSA) bilayers, and 3.44%
paclitaxel was released from particles having three (PDDA-PSS) bilayers.
Figure 6.14 depicts the sustained release curve for paclitaxel coated with 3
bilayers of biocompatible PS and HSA for 8 hrs at sink conditions at pH 7.3. As
demonstrated, these nanoparticles have sustained release for over 500 minutes.
Brief Description of the Drawings
Figures 6.1 through 6.14 are presented for the purpose of illustration only, and are
not intended to be limiting.
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Figure 6.1 A diagrammatic representation of a method for making a nanoparticle of the
invention.
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Figure 6.2 A diagrammatic representation of a method of conjugation of an antibody to a
nanoparticle of the invention. (Adapted from the book Bioconjugate Techniques by Greg
Hermanson)
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Figure 6.3 A graphic representation of the particle size of nanoparticles containing
tamoxifen or paclitaxel particle size following various durations of sonication.
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Figure 6.4 A graphic representation of the zeta potential obtained from tamoxifen
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Figure 6.5 A graphic representation of zeta potentials obtained from the addition of PAH
and PDDA onto paclitaxel (2.5 mg/ml) containing nanoparticles.

Figure 6.6 A representation of a scanning electron microscopy (SEM) image of
tamoxifen-containing nanoparticles with 2 mg/ml PAH at low magnification.
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Figure 6.7 Representations of SEM images of tamoxifen-containing nanoparticles at
higher magnification.
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Figure 6.8 (a) Apparatus for crypgenic sonication and (b) picture taken during cryogenic
sonication with Liquid Nitrogen surrounding the drug sample. The sample temperatures
after sonication were measured with an Infra-Red Thermometer Gun.
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Figure 6.9 (a) Representation of an SEM image of paclitaxel (2 mg/ml) sonicated for 10
minute at 18 W on ice without any polyelectrolyte. (b) Representation of an SEM image
of paclitaxel (2 mg/ml) sonicated for 10 minute at 18 W surrounded by liquid nitrogen
without any polyelectrolyte.
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Figure 6.10 (a)-(b) Representation of an SEM image of paclitaxel (2 mg/ml) particles
obtained after two bilayer deposition (PAH-PSS)2.
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a)

b)

Figure 6.11(a) Representation of a confocal fluorescent image of an aqueous dispersion
of tamoxifen-containing nanoparticles coated with FITC-labeled PAH along with (b)
transmission image.

40 -I
RTC-PAH-20min

30-

FITC-PAH-30min

FITC-PAH-10min

20-

}

10-

/

I 0|-10N
-20-

/

-30-40-50-

\

Mesotetf-aphen^Jporphyrin
(4 mg/mlj

a)

b)

Figure 6.12 A graphic representation of (a) zeta potentials of Araeso-tetraphenylporphyrin
containing nanoparticles coated with FITC-PAH (b) showing SEM image of the drug
with particle size from 83 to 194 nanometers.
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Equivalents
It is to be understood that while the invention has been described in conjunction
with the detailed description thereof, the foregoing description is intended to illustrate
and not limit the scope of the invention, which is defined by the scope of the appended
claims.

Other aspects, advantages, and modifications are within the scope of the

following claims.

Claims
1.

A stable nanoparticle comprising:
(a) a compound;
(b) a first defined solid polymeric layer comprising a first polymer, the first layer

surrounding the compound; and
(c) a second defined solid polymeric layer comprising a second polymer, the
second layer surrounding the first layer,
the first polymer and the second polymer having opposite charges, and the nanoparticle
having a diameter of about 100 nm to about 500 nm.
2.

The nanoparticle of claim 1, wherein the compound is present at about 5% by

weight to about 95% by weight.
3.

The nanoparticle of claim 1, wherein the first polymeric layer and the second

polymeric layer have a combined thickness of about 5 nm to about 30 nm.
4.

The nanoparticle of claim 1, wherein the first polymer is positively charged and

the second polymer is negatively charged.
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5.

The nanoparticle of claim 1, further comprising a third polymeric layer

surrounding the second polymeric layer, the third polymeric layer comprising a third
polymer having an opposite charge from the second polymer.
6.

The nanoparticle of claim 5, wherein the first polymer and the third polymer are

the same.
7.

The nanoparticle of claim 1, wherein the solubility of the compound is very low.

8.

The nanoparticle of claim 1, wherein the second polymeric layer is modified with

a targeting agent.
9.

The nanoparticle of claim 5, wherein the third polymeric layer is modified with a

targeting agent.
10.

The nanoparticle of claim 8, wherein the targeting agent is an antibody.

11.

The nanoparticle of claim 9, wherein the targeting agent is an antibody.

12.

The nanoparticle of claim 1, wherein the nanoparticle does not contain a detergent

or a surfactant.
13.

The nanoparticle of claim 1, wherein the compound is released from the

nanoparticle at a rate dependent on the number of LbL coatings
14.

A nanoparticle comprising:
(a) a compound; and
(b) a polymeric coating comprised of alternating polymeric layers of oppositely
charged polymers; the nanoparticle having a diameter of about 100 nm to about
500 nm.

15.

The nanoparticle of claim 14, wherein the nanoparticle comprises two, three, four,

five, or six polymeric layers of oppositely charged polymers.
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16.

The nanoparticle of claim 14, wherein the compound is present at about 5% by

weight to about 95% by weight.
17.

The nanoparticle of claim 14, wherein the polymeric layers have a combined

thickness of about 5 ran to about 30 ran.
18.

A method of making a stable nanoparticle, the method comprising:

subjecting a water-insoluble compound to ultrasonication; and adding a first polymer to
the compound in the presence of ultrasonication, the polymer being added at a
concentration sufficient to form a stable first polymeric layer around the compound.
19.

The method of claim 18, wherein after ultrasonication, the water-insoluble

compound has a negative charge in the absence of the polymer.
20.

The method of claim 18, wherein the polymer added to the compound has a

positive charge.
21.

The method of claim 18, wherein the ultrasonication is performed at about 20 °C to

about 30 °C.
22.

A method of treating a subject having a tumor, the method comprising

administering to the subject a nanoparticle in an amount sufficient to reduce tumor size or
number of tumor cells, wherein the nanoparticle comprises:
(a) a compound;
(b) a first defined solid polymeric layer comprising a first polymer, the first layer
surrounding the compound; and
(c) a second defined solid polymeric layer comprising a second polymer, the
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second layer surrounding the first layer, the first polymer and the second polymer having
opposite charges, and the nanoparticle having a diameter of about 100 nm to about 500
nm.
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